{"id":"gadobutrol","rwe":[{"pmid":"41866988","year":"2026","title":"Efficacy of a Novel Dimeric Macrocyclic Gadolinium Chelate With High Relaxivity in Preclinical Models of Neurological and Oncological Pathologies.","finding":"","journal":"Investigative radiology","studyType":"Clinical Study"},{"pmid":"41864344","year":"2026","title":"Safety and T(1) Reactivity for Vasodilator Stress Ferumoxytol-Enhanced Cardiac Magnetic Resonance Imaging.","finding":"","journal":"Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance","studyType":"Clinical Study"},{"pmid":"41819032","year":"2026","title":"Safety and utility of subcutaneous gadobutrol-enhanced MR lymphography for preoperative mapping in lymphovenous anastomosis: A phase II trial.","finding":"","journal":"Journal of plastic, reconstructive & aesthetic surgery : JPRAS","studyType":"Clinical Study"},{"pmid":"41720517","year":"2026","title":"Gadolinium-Enhanced Portable Ultra-Low Field MRI for Evaluating Various Intracranial Pathologies.","finding":"","journal":"AJNR. American journal of neuroradiology","studyType":"Clinical Study"},{"pmid":"41698691","year":"2026","title":"LC-MS/MS-Based Determination of Gadobutrol Residues for Pharmaceutical Cleaning Validation.","finding":"","journal":"PDA journal of pharmaceutical science and technology","studyType":"Clinical Study"}],"_fda":{"id":"490c8c3e-3195-40af-8f34-40d8df2719c3","risks":["Risk Summary GBCAs cross the placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive (see Data ) . In animal reproduction studies, although teratogenicity was not observed, embryolethality was observed in monkeys, rabbits and rats receiving intravenous gadobutrol during organogenesis at doses 8 times and above the recommended human dose. Retardation of embryonal development was observed in rabbits and rats receiving intravenous gadobutrol during organogenesis at doses 8 and 12 times, respectively, the recommended human dose (see Data ). Because of the potential risks of gadolinium to the fetus, use gadobutrol injection only if imaging is essential during pregnancy and cannot be delayed. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and is 15% to 20%, respectively.","Risk Summary There are no data on the presence of gadobutrol in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01% to 0.04% of the maternal gadolinium dose is present in breast milk and there is limited GBCA gastrointestinal absorption in the breast-fed infant. Gadobutrol is present in rat milk (see Data ). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for gadobutrol injection and any potential adverse effects on the breastfed infant from gadobutrol injection or from the underlying maternal condition."],"set_id":"007696d0-4b62-4937-9640-4ad619504df4","openfda":{"nui":["N0000183362","N0000175862"],"upc":["0365219281023"],"unii":["1BJ477IO2L"],"route":["INTRAVENOUS"],"spl_id":["490c8c3e-3195-40af-8f34-40d8df2719c3"],"brand_name":["Gadobutrol"],"spl_set_id":["007696d0-4b62-4937-9640-4ad619504df4"],"package_ndc":["65219-281-00","65219-281-02","65219-281-03","65219-281-07","65219-281-08","65219-281-10","65219-281-05","65219-281-15"],"product_ndc":["65219-281"],"generic_name":["GADOBUTROL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["GADOBUTROL"],"pharm_class_epc":["Gadolinium-based Contrast Agent [EPC]"],"pharm_class_moa":["Magnetic Resonance Contrast Activity [MoA]"],"manufacturer_name":["Fresenius Kabi USA, LLC"],"application_number":["ANDA215061"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk Summary GBCAs cross the placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive (see Data ) . In animal reproduction studies, although teratogenicity was not observed, embryolethality was observed in monkeys, rabbits and rats receiving intravenous gadobutrol during organogenesis at doses 8 times and above the recommended human dose. Retardation of embryonal development was observed in rabbits and rats receiving intravenous gadobutrol during organogenesis at doses 8 and 12 times, respectively, the recommended human dose (see Data ). Because of the potential risks of gadolinium to the fetus, use gadobutrol injection only if imaging is essential during pregnancy and cannot be delayed. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and is 15% to 20%, respectively. Data Human Data Contrast enhancement is visualized in the placenta and fetal tissues after maternal GBCA administration. Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported a clear association between GBCAs and adverse effects in the exposed neonates. However, a retrospective cohort study, comparing pregnant women who had a GBCA MRI to pregnant women who did not have an MRI, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include a lack of comparison with non-contrast MRI and lack of information about the maternal indication for MRI. Overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy. Animal Data Gadolinium Retention GBCAs administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. GBCAs administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one month postnatal age. Reproductive Toxicology Embryolethality was observed when gadobutrol was administered intravenously to monkeys during organogenesis at doses 8 times the recommended single human dose (based on body surface area); gadobutrol was not maternally toxic or teratogenic at this dose. Embryolethality and retardation of embryonal development also occurred in pregnant rats receiving maternally toxic doses of gadobutrol (≥ 7.5 mmol/kg body weight; equivalent to 12 times the human dose based on body surface area) and in pregnant rabbits (≥ 2.5 mmol/kg body weight; equivalent to 8 times the recommended human dose based on body surface area). In rabbits, this finding occurred without evidence of pronounced maternal toxicity and with minimal placental transfer (0.01% of the administered dose detected in the fetuses). Because pregnant animals received repeated daily doses of gadobutrol injection, their overall exposure was significantly higher than that achieved with the standard single dose administered to humans."],"overdosage":["10 OVERDOSAGE The maximum dose of gadobutrol injection tested in healthy volunteers, 1.5 mL/kg body weight (1.5 mmol/kg; 15 times the recommended dose), was tolerated in a manner similar to lower doses. Gadobutrol can be removed by hemodialysis [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12.3 )] ."],"description":["11 DESCRIPTION Gadobutrol injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging. The chemical name for gadobutrol is 10–[(1SR,2RS)–2,3–dihydroxy–1–hydroxymethylpropyl]–1,4,7,10–tetraazacyclododecane–1,4,7–triacetic acid, gadolinium complex. Gadobutrol has a molecular formula of C 18 H 31 GdN 4 O 9 and a molecular weight of 604.72. Gadobutrol injection is a sterile, clear, colorless to pale yellow solution containing 604.72 mg (1.0 mmol) of gadobutrol per mL as the active ingredient with 0.513 mg of calcobutrol sodium, 1.211 mg of trometamol, hydrochloric acid (for pH adjustment) and water for injection. Gadobutrol injection contains no preservatives. The main physicochemical properties of gadobutrol injection (1 mmol/mL solution for injection) are listed below: Density (g/mL at 37°C) 1.3 Osmolarity at 37°C (mOsm/L solution) 1,117 Osmolality at 37°C (mOsm/kg H 2 O) 1,603 Viscosity at 37°C (mPa·s) 4.96 pH 6.6 to 8 The thermodynamic stability constants for gadobutrol (log Ktherm and log Kcond at pH 7.4) are 21.8 and 15.3, respectively. gadob-struc-01.jpg"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Gadobutrol injection is a sterile, clear and colorless to pale yellow solution containing 604.72 mg gadobutrol per mL (equivalent to 1 mmol gadobutrol) per mL. Gadobutrol injection is supplied in the following sizes: Product Code Unit of Sale Each 281202 NDC 65219-281-02 Packaged in a Box of 5 Cartons containing 3 vials each. (15 total vials) NDC 65219-281-00 2 mL Single-Dose Vial with rubber stopper. 281207 NDC 65219-281-07 Packaged in a Box of 2 Cartons containing 10 vials each. (20 total vials) NDC 65219-281-03 7.5 mL Single-Dose Vial with rubber stopper. 281210 NDC 65219-281-10 Packaged in a Box of 2 Cartons containing 10 vials each. (20 total vials) NDC 65219-281-08 10 mL Single-Dose Vial with rubber stopper. 281205 NDC 65219-281-15 Packaged in a Box of 2 Cartons containing 10 vials each. (20 total vials) NDC 65219-281-05 15 mL Single-Dose Vial with rubber stopper. 16.2 Storage and Handling Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Should freezing occur, gadobutrol injection should be brought to room temperature before use. If allowed to stand at room temperature, gadobutrol injection should return to a clear and colorless to pale yellow solution. Visually inspect gadobutrol injection for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored, if particulate matter is present or if the container appears damaged."],"spl_medguide":["MEDICATION GUIDE Gadobutrol (GAD oh BUE trol) Injection Injection, for intravenous use What is the most important information I should know about gadobutrol injection? • GBCAs like Gadobutrol injection may cause serious side effects including death, coma, encephalopathy, and seizures when it is given intrathecally (injection given into the spinal canal). It is not known if Gadobutrol injection is safe and effective with intrathecal use. Gadobutrol injection is not approved for this use. • Gadobutrol injection contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years). • It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys. • Rarely, patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium. • There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance. Gadolinium stays in the body the least after Dotarem, Gadobutrol injection, or ProHance. • People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body. • Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive gadobutrol injection. What is gadobutrol injection? • Gadobutrol injection is a prescription medicine called a gadolinium-based contrast agent (GBCA). Gadobutrol injection, like other GBCAs, is injected into your vein and used with a magnetic resonance imaging (MRI) scanner. • An MRI exam with a GBCA, including gadobutrol injection, helps your doctor to see problems better than an MRI exam without a GBCA. • Your doctor has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam. Do not receive gadobutrol injection if you have had a severe allergic reaction to gadobutrol injection. Before receiving gadobutrol injection, tell your healthcare provider about all your medical conditions, including if you: • have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures. • are pregnant or plan to become pregnant. It is not known if gadobutrol injection can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as gadobutrol injection is received during pregnancy. • have kidney problems, diabetes, or high blood pressure • have had an allergic reaction to dyes (contrast agents) including GBCAs What are the possible side effects of gadobutrol injection? • See “What is the most important information I should know about gadobutrol injection?” • Allergic reactions. Gadobutrol injection can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction. • A serious lung problem called acute respiratory distress syndrome (ARDS). Call your healthcare provider right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing after receiving gadobutrol injection. The most common side effects of gadobutrol injection include: headache, nausea, and dizziness. These are not all the possible side effects of gadobutrol injection. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of gadobutrol injection. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about gadobutrol injection that is written for health professionals. What are the ingredients in gadobutrol injection? Active ingredient: gadobutrol Inactive ingredients: calcobutrol sodium, tromethamine, hydrochloric acid (for pH adjustment) and water for injection Manufactured for: Lake Zurich, IL 60047 www.fresenius-kabi.com/us For more information, call Fresenius Kabi USA, LLC at 1-800-551-7176 Product of China 451778C This Medication Guide has been approved by the U.S. Food and Drug Administration. 5/2025 26AUF04 gadob-img-02.jpg"],"boxed_warning":["WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadobutrol injection is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of drugs. Avoid use of gadobutrol injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. • The risk for NSF appears highest among patients with: o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or o Acute kidney injury. • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. • For patients at highest risk for NSF, do not exceed the recommended gadobutrol injection dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration [see Warnings and Precautions ( 5.2 )] . WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS See full prescribing information for complete boxed warning • Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadobutrol injection is not approved for intrathecal use ( 5.1 ) • GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of drugs. Avoid use of gadobutrol injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. • The risk for NSF appears highest among patients with: o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or o Acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. ( 5.2 )."],"geriatric_use":["8.5 Geriatric Use In clinical studies of gadobutrol injection, 1,377 patients were 65 years of age and over, while 104 patients were 80 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, use of gadobutrol injection in elderly patients should be cautious, reflecting the greater frequency of impaired renal function and concomitant disease or other drug therapy. No dose adjustment according to age is necessary in this population."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of gadobutrol injection have been established in pediatric patients, including term neonates, for use with MRI to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system and for use in MRA to evaluate known or suspected supra-aortic or renal artery disease. Use of gadobutrol injection in these indications is supported by adequate and well-controlled studies in adults and supportive imaging data in two studies in 135 patients 2 to less than 18 years of age and 44 patients less than 2 years of age with CNS and non-CNS lesions, and pharmacokinetic data in 130 patients 2 to less than 18 years of age and 43 patients less than 2 years of age, including term neonates [ see Clinical Pharmacology ( 12.3 ), and Clinical Studies ( 14.1 ) ]. The frequency, type, and severity of adverse reactions in pediatric patients were similar to adverse reactions in adults [see Adverse Reactions ( 6.1 )] . No dose adjustment according to age is necessary in pediatric patients [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.3 ), and Clinical Studies ( 14.1 )] . The safety and effectiveness of gadobutrol injection have not been established in preterm neonates for any indication or in pediatric patients of any age for use with MRI to assess the presence and extent of malignant breast disease, or for use in CMRI to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in patients with known or suspected coronary artery disease (CAD). NSF Risk No case of NSF associated with gadobutrol injection or any other GBCA has been identified in pediatric patients ages 6 years and younger. Pharmacokinetic studies suggest that clearance of gadobutrol injection is similar in pediatric patients and adults, including pediatric patients age younger than 2 years. No increased risk factor for NSF has been identified in juvenile animal studies of gadobutrol. Normal estimated GFR (eGFR) is around 30 mL/min/1.73m 2 at birth and increases to mature levels around 1 year of age, reflecting growth in both glomerular function and relative body surface area. Clinical studies in pediatric patients younger than 1 year of age have been conducted in patients with the following minimum eGFR: 31 mL/min/1.73m 2 (age 2 to 7 days), 38 mL/min/1.73m 2 (age 8 to 28 days), 62 mL/min/1.73m 2 (age 1 to 6 months), and 83 mL/min/1.73m 2 (age 6 to 12 months). Juvenile Animal Data Single and repeat-dose toxicity studies in neonatal and juvenile rats did not reveal findings suggestive of a specific risk for use in pediatric patients including term neonates and infants."],"effective_time":"20250715","clinical_studies":["14 CLINICAL STUDIES 14.1 MRI of the CNS Patients referred for MRI of the central nervous system with contrast were enrolled in two clinical trials that evaluated the visualization characteristics of lesions. In both studies, patients underwent a baseline, pre-contrast MRI prior to administration of gadobutrol injection at a dose of 0.1 mmol/kg, followed by a post-contrast MRI. In Study A, patients also underwent an MRI before and after the administration of gadoteridol. The studies were designed to demonstrate superiority of gadobutrol injection MRI to non-contrast MRI for lesion visualization. For both studies, pre-contrast and pre-plus-post contrast images (paired images) were independently evaluated by three readers for contrast enhancement and border delineation using a scale of 1 to 4, and for internal morphology using a scale of 1 to 3 ( Table 5 ). Lesion counting was also performed to demonstrate non-inferiority of paired gadobutrol injection image sets to pre-contrast MRI. Readers were blinded to clinical information. Table 5: Primary Endpoint Visualization Scoring System Score Visualization Characteristics Contrast Enhancement Border Delineation Internal Morphology 1 None None Poorly visible 2 Weak Moderate Moderately visible 3 Clear Clear but incomplete Sufficiently visible 4 Clear and bright Clear and complete N/A Efficacy was determined in 657 subjects. The average age was 49 years (range 18 to 85 years) and 42% were male. The ethnic representations were 39% Caucasian, 4% Black, 16% Hispanic, 38% Asian, and 3% of other ethnic groups. Table 6 shows a comparison of visualization results between paired images and pre-contrast images. Gadobutrol injection provided a statistically significant improvement for each of the three lesion visualization parameters when averaged across three independent readers for each study. Table 6: Visualization Endpoint Results of Central Nervous System Adult MRI Studies with 0.1 mmol/kg Gadobutrol Injection Endpoint Study A N=336 Study B N=321 Pre-contrast Paired Difference Difference of means = (paired mean) – (pre-contrast mean) Pre-contrast Paired Difference Contrast Enhancement 0.97 2.26 1.29 p<0.001 0.93 2.86 1.94 Border Delineation 1.98 2.58 0.60 1.92 2.94 1.02 Internal Morphology 1.32 1.93 0.60 1.57 2.35 0.78 Average # Lesions Detected 8.08 8.25 0.17 Did not meet noninferiority margin of -0.35 2.65 2.97 0.32 Met noninferiority margin of -0.35 Performances of gadobutrol and gadoteridol for visualization parameters were similar. Regarding the number of lesions detected, Study B met the prespecified noninferiority margin of -0.35 for paired read versus pre-contrast read while in Study A, gadobutrol and gadoteridol did not. For the visualization endpoints contrast enhancement, border delineation, and internal morphology, the percentage of patients scoring higher for paired images compared to pre-contrast images ranged from 93% to 99% for Study A, and 95% to 97% for Study B. For both studies, the mean number of lesions detected on paired images exceeded that of the pre-contrast images; 37% for Study A and 24% for Study B. There were 29% and 11% of subjects in which the pre-contrast images detected more lesions for Study A and Study B, respectively. The percentage of patients whose average reader mean score changed by ≤ 0, up to 1, up to 2, and ≥ 2 scoring categories presented in Table 5 is shown in Table 7 . The categorical improvement of (≤ 0) represents higher (< 0) or identical (= 0) scores for the pre-contrast read, the categories with scores > 0 represent the magnitude of improvement seen for the paired read. Table 7: Primary Endpoint Visualization Categorical Improvement for Average Reader Study A N=336 Study B N=321 Endpoint Categorical Improvement (Paired – Pre-Contrast) % Categorical Improvement (Paired – Pre-Contrast) % ≤ 0 > 0 to < 1 1 to < 2 ≥ 2 ≤ 0 > 0 to < 1 1 to < 2 ≥ 2 Contrast Enhancement 1 30 55 13 3 6 34 57 Border Delineation 7 73 18 1 5 38 51 5 Internal Morphology 4 79 17 0 5 61 33 1 For both studies, the improvement of visualization endpoints in paired gadobutrol injection images compared to pre-contrast images resulted in improved assessment of normal and abnormal CNS anatomy. Pediatric Patients Two studies in 44 pediatric patients age younger than 2 years and 135 pediatric patients age 2 to less than 18 years with CNS and non-CNS lesions supported extrapolation of adult CNS efficacy findings. For example, comparing pre vs paired pre- and post-contrast images, investigators selected the best of four descriptors under the heading, “Visualization of lesion-internal morphology (lesion characterization) or homogeneity of vessel enhancement” for 27/44 (62% = pre) vs 43/44 (98% = paired) MR images from patients age 0 to less than 2 years and 106/135 (78% = pre) vs 108/135 (80% = paired) MR images from patients age 2 to less than 18 years. 14.2 MRI of the Breast Patients with recently diagnosed breast cancer were enrolled in two identical clinical trials to evaluate the ability of gadobutrol injection to assess the presence and extent of malignant breast disease prior to surgery. Patients underwent non-contrast breast MRI (BMR) prior to gadobutrol injection (0.1 mmol/kg) breast MRI. BMR images and gadobutrol injection BMR (combined contrast plus non-contrast) images were independently evaluated in each study by three readers blinded to clinical information. In separate reading sessions the BMR images and gadobutrol injection BMR images were also interpreted together with X-ray mammography images (XRM). The studies evaluated 787 patients: Study 1 enrolled 390 women with an average age of 56 years, 74% were white, 25% Asian, 0.5% black, and 0.5% other; Study 2 enrolled 396 women and 1 man with an average age of 57 years, 71% were white, 24% Asian, 3% black, and 2% other. The readers assessed 5 regions per breast for the presence of malignancy using each reading modality. The readings were compared to an independent standard of truth (SoT) consisting of histopathology for all regions where excisions were made and tissue evaluated. XRM plus ultrasound was used for all other regions. The assessment of malignant disease was performed using a region based within-subject sensitivity. Sensitivity for each reading modality was defined as the mean of the percentage of malignant breast regions correctly interpreted for each subject. The within-subject sensitivity of gadobutrol injection BMR was superior to that of BMR. The lower bound of the 95% Confidence Interval (CI) for the difference in within-subject sensitivity ranged from 19% to 42% for Study 1 and from 12% to 27% for Study 2. The within-subject sensitivity for gadobutrol injection BMR and BMR as well as for gadobutrol injection BMR plus XRM and BMR plus XRM is presented in Table 8 . Table 8: Sensitivity of Gadobutrol Injection BMR for Detection of Malignant Breast Disease Study 1 Study 2 Sensitivity (%) N=388 Patients Sensitivity (%) N=390 Patients Reader BMR BMR + XRM Gadobutrol Injection BMR Gadobutrol Injection BMR +XRM Reader BMR BMR + XRM Gadobutrol Injection BMR Gadobutrol Injection BMR +XRM 1 37 71 83 84 4 73 83 87 90 2 49 76 80 83 5 57 81 89 90 3 63 75 87 87 6 55 80 86 88 Specificity was defined as the percentage of non-malignant breasts correctly identified as non-malignant. The lower limit of the 95% confidence interval for specificity of gadobutrol injection BMR was greater than 80% for 5 of 6 readers. ( Table 9 ) Table 9: Specificity of Gadobutrol Injection BMR in Non-Malignant Breasts Study 1 Study 2 Specificity (%) N=372 Patients Specificity (%) N=367 Patients Reader Gadobutrol Injection BMR Lower Limit 95% CI Reader Gadobutrol Injection BMR Lower Limit 95% CI 1 86 82 4 92 89 2 95 93 5 84 80 3 89 85 6 83 79 Three additional readers in each study read XRM alone. For these readers over both studies, sensitivity ranged from 68% to 73% and specificity in non-malignant breasts ranged from 86% to 94%. In breasts with malignancy, a false positive detection rate was calculated as the percentage of subjects for which the readers assessed a region as malignant which could not be verified by SoT. The false positive detection rates for gadobutrol injection BMR ranged from 39% to 53% (95% CI Upper Bounds ranged from 44% to 58%). 14.3 MRA Patients with known or suspected disease of the supra-aortic arteries (for evaluation up to but excluding the basilar artery) were enrolled in Study C, and patients with known or suspected disease of the renal arteries were enrolled in Study D. In both studies, non-contrast, 2D time-of-flight (ToF) magnetic resonance angiography (MRA) was performed prior to gadobutrol injection MRA using a single intravenous injection of 0.1 mmol/kg. The injection rate of 1.5 mL/second was selected to extend the injection duration to at least half of the imaging duration. Imaging was performed with parallel-channel, 1.5T MRI devices and an automatic bolus tracking technique to trigger the image acquisition following gadobutrol injection administration using elliptically encoded, T1-weighted, 3D gradient-echo image acquisition and single breath hold. Three central readers blinded to clinical information interpreted the ToF and gadobutrol injection MRA images. Three additional central readers interpreted separately acquired computed tomographic angiography (CTA) images, which were used as the standard of reference (SoR) in each study. The studies included 749 subjects: 457 were evaluated in Study C, with an average age of 68 (range 25 to 93); 64% were male; 80% white, 28% black, and 16% Asian. An additional 292 subjects were evaluated in Study D, with an average age of 55 (range 18 to 88); 54% were male; 68% white, 7% black, and 22% Asian. Efficacy was evaluated based on anatomical visualization and performance for distinguishing between normal and abnormal anatomy. The visualization metric depended on whether readers selected, “Yes, it can be visualized along its entire length.” when responding to the question, “Is this segment assessable?” Twenty-one segments in Study C and six segments in Study D were presented per subject to each reader. The performance metrics, sensitivity and specificity, depended on digital caliper-based quantitation of arterial narrowing in visualized, non-occluded, abnormal-appearing segments. Significant stenosis was defined as at least 70% in Study C and 50% in Study D. Performance of gadobutrol injection MRA compared to ToF MRA was calculated using an imputation method for non-visualized segments by assigning them as a 50% match with SoR and a 50% mismatch. Performance of gadobutrol injection MRA compared to a pre-specified threshold of 50% was calculated after excluding non-visualized segments. Measurement variability and visualization of accessory renal arteries was also evaluated. Results were analyzed for each of the three central readers. Table 10: Visualization, Sensitivity, Specificity STUDY C: SUPRA-AORTIC ARTERIES (457 patients) Performance at the segment level 9,597 Number of segments varied between readers; number for majority-reader shown . segments of which 158 were positive for stenosis by SoR Standard of Reference based on aggregate interpretation of three central CTA readers. VISUALIZATION (%) SENSITIVITY (%) SPECIFICITY (%) READER GAD MRA ToF MRA GAD - ToF (CI 95.1/95% (Study C/D) confidence interval for two-sided comparison. ) GAD MRA ToF MRA GAD - ToF (CI 90.1/90% (Study C/D) confidence interval for one-sided comparison against non-inferiority margin of -7.5. GAD MRA = Post-contrast Gadobutrol Injection Magnetic Resonance Angiography, ToF = Non-contrast 2D-Time of Flight. ) GAD MRA ToF MRA GAD - ToF (CI ) 1 88 24 64 (61, 67) 60 54 6 (-4, 14) 92 62 30 (29, 32) 2 95 75 20 (18, 21) 60 54 6 (-3, 14) 95 85 10 (9, 11) 3 97 82 15 (13, 17) 58 55 3 (-4, 11) 97 89 8 (7, 9) STUDY D: RENAL ARTERIES (292 patients) Performance at the segment level 1,752 * segments of which 133 * were positive for stenosis by SoR † 4 98 82 16 (13, 20) 52 51 1(-9, 11) 94 83 11 (9, 14) 5 96 72 24 (21, 28) 54 39 15 (6, 24) 95 85 10 (8, 12) 6 96 78 17 (14, 21) 53 50 3 (-6, 12) 94 81 13 (11, 16) For all three supra-aortic artery readers in Study C, the lower bound of confidence for the sensitivity of gadobutrol injection MRA did not exceed 54%. For all three renal artery readers in Study D, the lower bound of confidence for the sensitivity of gadobutrol injection MRA did not exceed 46%. Measurement Variability For both MRA and CTA, readers varied in the quantity of narrowing they assigned to the same arterial segments. Table 11 shows the percentage of patients in whom the measurement range was 30% or greater for the left or right internal carotid and proximal renal artery segments. There were approximately four measurements per patient segment, one from the site and three central readers. Measurement variability was high for both CTA and MRA, but numerically lower for gadobutrol injection compared to non-contrast ToF MRA. Table 11: Percent of Patients with Range ≥ 30%, ≥ 50%, ≥ 70% for Measurement of Stenoses and Normal Vessel Diameters Internal Carotid Proximal Main Renal N ≥ 30% ≥ 50% ≥ 70% N ≥ 30% ≥ 50% ≥ 70% CTA 456 40 11 4 292 59 33 9 ToF MRA 443 55 22 9 270 44 22 9 Gadobutrol Injection MRA 454 47 13 4 286 34 14 4 Visualization of Accessory Renal Arteries for Surgical Planning and Renal Donor Evaluation (Study D only) Of 1,752 main arteries visualized by the central CTA readers, 266 (15%) were also associated with positive visualization of at least one accessory (duplicate) artery. With the central MRA readers, the comparable rates were 232 of 1,752 (13%) for gadobutrol injection MRA compared to 53 of 1,752 (3%) for ToF MRA. 14.4 Cardiac MRI Two studies similar in design, Study E and Study F, evaluated the sensitivity and specificity of gadobutrol injection cardiac MRI (CMRI) for detection of coronary artery disease (CAD) in adult patients with known or suspected CAD. Patients were excluded from study if they had a history of coronary artery bypass grafting, or if it was known in advance that they were unable to hold their breath, or had atrial fibrillation or other arrhythmia likely to prevent electrocardiogram-gated CMRI. The studies were multi-center, open-label, and evaluated 764 subjects for efficacy: 376 in Study E, with an average age of 59 (range 20 to 84); 69% male; 74% white, 1% black, and 25% Asian; and 388 subjects in Study F, with an average age of 59 (range 23 to 82); 61% male; 67% white, 17% black, and 12% Asian. All subjects underwent dynamic first-pass gadobutrol injection imaging during vasodilator stress, followed ~10 minutes later by dynamic first-pass gadobutrol injection imaging at rest, followed ~5 minutes later with imaging during a period of gradual gadobutrol injection washout from the myocardium (late gadolinium enhancement, LGE). Imaging was performed on 1.5 T or 3.0 T MRI devices equipped with multichannel surface coils to support accelerated acquisitions with parallel imaging, T1-weighted, 2D gradient-echo, dynamic acquisition of perfusion with at least 3 slices per heartbeat. Gadobutrol injection was administered intravenously at a rate of ~4 mL/second as two separate bolus injections (0.05 mmol/kg each), the first at peak pharmacologic stress (~3 minutes after start of ongoing adenosine infusion, or immediately after completion of regadenoson administration, at approved doses). No additional gadobutrol injection was administered for LGE imaging. Images were read by three independent readers blinded to clinical information. Reader detection of CAD depended on visually detecting defective perfusion or scar on gadobutrol injection CMRI (stress, rest, LGE) imaging. Quantitative coronary angiography (QCA) was used to measure intraluminal narrowing and served as the standard of reference (SoR). Computed tomographic angiography (CTA) was used as the SoR if disease could be unequivocally excluded, and no coronary angiography (CA) was available. The left ventricular myocardium was divided into six regions. Readers provided per-region (CMRI, CTA) and per-artery (QCA) interpretations for each subject. Subject-level endpoints reflected each subject's most abnormal localized finding. The sensitivity results for gadobutrol injection CMRI to detect CAD defined as either maximum stenosis ≥50% or ≥70% by QCA are presented in Table 12 . For each reader, sensitivity of gadobutrol injection CMRI larger than 60% can be concluded if the lower 95% confidence limit of the sensitivity estimate exceeds the pre-specified threshold of 60%. Table 12: Sensitivity (%) of Gadobutrol Injection CMRI for Detection of CAD in Patients with Maximum Stenosis* of ≥50% and ≥70% Study E Study F ≥50% N=141 ≥70% N=108 ≥50% N=150 ≥70% N=105 Reader 1** 77 ( 69 , 83)*** 90 ( 83 , 95) 65 ( 57 , 72) 77 ( 68 , 85) Reader 2** 65 ( 57 , 73) 80 ( 71 , 87) 56 ( 48 , 64) 71 ( 62 , 80) Reader 3** 65 ( 56 , 72) 79 ( 70 , 86) 61 ( 53 , 69) 76 ( 67 , 84) * Stenosis determined by Quantitative Coronary Angiography (QCA) ** CMRI images were assessed by six independent blinded readers, three in each study. *** The bolded value represents the lower limit of the 95% confidence interval, which is compared to a pre-specified threshold of 60% for evaluation of sensitivity. The specificity results for gadobutrol injection CMRI to detect CAD defined as either maximum stenosis ≥50% or ≥70% by QCA are presented in Table 13 . For each reader, specificity of gadobutrol injection CMRI larger than 55% can be concluded if the lower 95% confidence limit of the specificity estimate exceeds the pre-specified threshold of 55%. Table 13: Specificity (%) of Gadobutrol Injection CMRI for Exclusion of CAD in Patients with Maximum Stenosis* of ≥50% and ≥70% Study E Study F ≥50% N=235 ≥70% N=268 ≥50% N=239 ≥70% N=283 Reader 1** 85 ( 80 , 89)*** 83 ( 78 , 87) 85 ( 80 , 90) 82 ( 77 , 86) Reader 2** 92 ( 88 , 95) 91 ( 87 , 94) 89 ( 84 , 92) 87 ( 83 , 91) Reader 3** 92 ( 88 , 95) 91 ( 87 , 94) 90 ( 85 , 93) 87 ( 82 , 91) * Stenosis determined by Quantitative Coronary Angiography (QCA) ** CMRI images were assessed by six independent blinded readers, three in each study. *** The bolded value represents the lower limit of the 95% confidence interval, which is compared to a pre-specified threshold of 55% for evaluation of specificity. In Study E, among the 33 patients with maximum stenosis by QCA between 50% and <70%, the proportion of gadobutrol injection-CMRI positive detections of CAD ranged from 15% to 33% . In Study F, among the 45 patients with maximum stenosis by QCA between 50% and < 70%, the proportion of gadobutrol injection-CMRI positive detections of CAD ranged from 20% to 35%. The results of gadobutrol injection-CMRI reads to detect CAD in patients with maximum stenosis between 50% and < 70% are summarized in Table 14 . Table 14: Gadobutrol Injection-CMRI Detection of CAD in Patients with Maximum Stenosis* between 50% and < 70% Study E (n=33) Study F (n=45) Gadobutrol Injection-CMRI positive Gadobutrol Injection-CMRI positive Reader 1** 11 (33%) 16 (35%) Reader 2** 5(15%) 9 (20%) Reader 3** 6(18%) 12 (26%) * Stenosis determined by Quantitative Coronary Angiography (QCA). **CMRI images were assessed by six independent blinded readers, three in each study. Left Mainstem Stenosis (LMS) The studies did not include sufficient numbers of subjects to characterize the performance of gadobutrol injection CMRI for detection of LMS, a subgroup at high risk from false negative reads. In Studies E and F, only three subjects had isolated LMS stenosis >50%. In two of the three cases, the CMRI was interpreted as normal by at least two of the three readers (false negative). Sixteen subjects had LMS stenosis >50% (including subjects with isolated LMS stenosis and subjects with LMS stenosis in addition to stenoses elsewhere). In five of these sixteen cases, the CMR was interpreted as normal by at least two of the three readers (false negative)."],"pharmacodynamics":["12.2 Pharmacodynamics Gadobutrol leads to distinct shortening of the relaxation times even in low concentrations. At pH 7, 37°C and 1.5 T, the relaxivity (r 1 ) - determined from the influence on the relaxation times (T 1 ) of protons in plasma - is 5.2 L/(mmol·sec) and the relaxivity (r 2 ) - determined from the influence on the relaxation times (T 2 ) - is 6.1 L/(mmol·sec). These relaxivities display only slight dependence on the strength of the magnetic field. The T 1 shortening effect of paramagnetic contrast agents is dependent on concentration and r 1 relaxivity (see Table 3 ). This may improve tissue visualization. Table 3: Relaxivity (r 1 ) of Gadolinium Chelates at 1.5 T r 1 relaxivity in plasma at 37°C Gadolinium-Chelate r 1 (L·mmol -1 ·s -1 ) Gadobenate 6.3 Gadobutrol 5.2 Gadodiamide 4.3 Gadofosveset 16 Gadopentetate 4.1 Gadoterate 3.6 Gadoteridol 4.1 Gadoversetamide 4.7 Gadoxetate 6.9 Compared to 0.5 molar gadolinium-based contrast agents, the higher concentration of gadobutrol injection results in half the volume of administration and a more compact contrast bolus injection. At the site of imaging, the relative height and width of the time intensity curve for gadobutrol injection varies as a function of imaging location and multiple patient, injection, and device-specific factors. Gadobutrol is a water-soluble, hydrophilic compound with a partition coefficient between n-butanol and buffer at pH 7.6 of about 0.006."],"pharmacokinetics":["12.3 Pharmacokinetics Distribution After intravenous administration, gadobutrol is rapidly distributed in the extracellular space. After a gadobutrol dose of 0.1 mmol/kg body weight, an average level of 0.59 mmol gadobutrol/L was measured in plasma 2 minutes after the injection and 0.3 mmol gadobutrol/L 60 minutes after the injection. Gadobutrol does not display any particular protein binding. Following GBCA administration, gadolinium is present for months or years in brain, bone, skin, and other organs [see Warnings and Precautions ( 5.5 )] . Metabolism Gadobutrol is not metabolized. Elimination Values for AUC, body weight normalized plasma clearance and half-life are given in Table 4 , below. Gadobutrol is excreted in an unchanged form via the kidneys. In healthy subjects, renal clearance of gadobutrol is 1.1 to 1.7 mL/(min∙kg) and thus comparable to the renal clearance of inulin, confirming that gadobutrol is eliminated by glomerular filtration. Within two hours after intravenous administration more than 50% and within 12 hours more than 90% of the given dose is eliminated via the urine. Extra-renal elimination is negligible. Specific Populations Gender Gender has no clinically relevant effect on the pharmacokinetics of gadobutrol. Geriatric A single intravenous dose of 0.1 mmol/kg gadobutrol injection was administered to 15 elderly and 16 non-elderly subjects. AUC was slightly higher and clearance slightly lower in elderly subjects as compared to non-elderly subjects [see Use in Specific Populations ( 8.5 )] . Pediatric The pharmacokinetics of gadobutrol were evaluated in two studies in a total of 130 patients age 2 to less than 18 years and in 43 patients less than 2 years of age (including term neonates). Patients received a single intravenous dose of 0.1 mmol/kg of gadobutrol injection. The pharmacokinetic profile of gadobutrol in pediatric patients is similar to that in adults, resulting in similar values for AUC, body weight normalized plasma clearance, as well as elimination half-life. Approximately 99% (median value) of the dose was recovered in urine within 6 hours (this information was derived from the 2 to less than 18 year old age group). Table 4: Pharmacokinetics by Age Group (Median [Range]) 0 to < 2 years 2 to 6 years 7 to 11 years 12 to < 18 years Adults N=43 N=45 N=39 N=46 N=93 AUC (µmolxh/L) 781 [513, 1,891] 846 [412, 1,331] 1,025 [623, 2,285] 1,237 [946, 2,211] 1,072 [667, 1,992] CL (L/h/kg) 0.128 [0.053, 0.195] 0.119 [0.08, 0.215] 0.099 [0.043, 0.165] 0.081 [0.046, 0.103] 0.094 [0.051, 0.150] t 1/2 (h) 2.91 [1.60, 12.4] 1.91 [1.04, 2.70] 1.66 [0.91, 2.71] 1.68 [1.31, 2.48] 1.80 [1.20, 6.55] C 20 (µmol/L) 367 [280, 427] 421 [369, 673] 462 [392, 760] 511 [387, 1,077] 441 [281, 829] Renal Impairment In patients with impaired renal function, the serum half-life of gadobutrol is prolonged and correlated with the reduction in creatinine clearance. After intravenous injection of 0.1 mmol gadobutrol/kg body weight, the elimination half-life was 5.8 ± 2.4 hours in mild to moderately impaired patients (80 > CL CR > 30 mL/min) and 17.6 ± 6.2 hours in severely impaired patients not on dialysis (CL CR < 30 mL/min). The mean AUC of gadobutrol in patients with normal renal function was 1.1 ± 0.1 mmol∙h/L, compared to 4.0 ± 1.8 mmol∙h/L in patients with mild to moderate renal impairment and 11.5 ± 4.3 mmol∙h/L in patients with severe renal impairment. Complete recovery in the urine was seen in patients with mild or moderate renal impairment within 72 hours. In patients with severely impaired renal function about 80% of the administered dose was recovered in the urine within 5 days. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of gadobutrol injection in order to enhance the contrast agent’s elimination. Sixty-eight percent (68%) of gadobutrol is removed from the body after the first dialysis, 94% after the second dialysis, and 98% after the third dialysis session. [see Warnings and Precautions ( 5.2 ) and Use in Specific Populations ( 8.6 ).]"],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed elsewhere in labeling: • Nephrogenic Systemic Fibrosis (NSF) [see Boxed Warning and Warnings and Precautions ( 5.2 )] . • Hypersensitivity reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.3 )] . • Acute Respiratory Distress Syndrome [see Warnings and Precautions ( 5.4 )] . • Gadolinium Retention [see Warnings and Precautions ( 5.5 )] . Most common adverse reactions (incidence ≥ 0.5%) are headache, nausea, and dizziness ( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The adverse reactions described in this section reflect gadobutrol injection exposure in 7,713 subjects (including 184 pediatric patients, ages 0 to 17 years) with the majority receiving the recommended dose. Approximately 52% of the subjects were male and the ethnic distribution was 62% Caucasian, 28% Asian, 5% Hispanic, 2.5% Black, and 2.5% patients of other ethnic groups. The average age was 56 years (range from 1 week to 93 years). Overall, approximately 4% of subjects reported one or more adverse reactions during a follow-up period that ranged from 24 hours to 7 days after gadobutrol injection administration. Adverse reactions associated with the use of gadobutrol injection were usually mild to moderate in severity and transient in nature. Table 2 lists adverse reactions that occurred in ≥ 0.1% subjects who received gadobutrol injection. Table 2: Adverse Reactions Reaction Rate (%) n=7,713 Headache 1.7 Nausea 1.2 Dizziness 0.5 Dysgeusia 0.4 Feeling Hot 0.4 Injection site reactions 0.4 Vomiting 0.4 Rash (includes generalized, macular, papular, pruritic) 0.3 Erythema 0.2 Paresthesia 0.2 Pruritus (includes generalized) 0.2 Dyspnea 0.1 Urticaria 0.1 Adverse reactions that occurred with a frequency of < 0.1% in subjects who received gadobutrol injection include: hypersensitivity/anaphylactic reaction, loss of consciousness, convulsion, parosmia, tachycardia, palpitation, dry mouth, malaise and feeling cold. 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postmarketing use of gadobutrol injection or other GBCAs. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Cardiac arrest • Nephrogenic Systemic Fibrosis (NSF) • Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) • Respiratory, Thoracic, and Mediastinal Disorders: Acute respiratory distress syndrome, pulmonary edema • General Disorders and Administration Site Conditions: Adverse reactions with variable onset and duration have been reported after GBCA administration These include fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems . • Skin: Gadolinium associated plaques • Gastrointestinal Disorders: Acute pancreatitis with onset within 48 hours after GBCA administration"],"contraindications":["4 CONTRAINDICATIONS Gadobutrol injection is contraindicated in patients with history of severe hypersensitivity reactions to gadobutrol injection. History of severe hypersensitivity reaction to gadobutrol injection ( 4 )"],"description_table":["
Density (g/mL at 37°C)1.3
Osmolarity at 37°C (mOsm/L solution)1,117
Osmolality at 37°C (mOsm/kg H2O)1,603
Viscosity at 37°C (mPa·s)4.96
pH6.6 to 8
"],"how_supplied_table":["
Product CodeUnit of SaleEach
281202 NDC 65219-281-02 Packaged in a Box of 5 Cartons containing 3 vials each. (15 total vials) NDC 65219-281-00 2 mL Single-Dose Vial with rubber stopper.
281207 NDC 65219-281-07 Packaged in a Box of 2 Cartons containing 10 vials each. (20 total vials) NDC 65219-281-03 7.5 mL Single-Dose Vial with rubber stopper.
281210 NDC 65219-281-10 Packaged in a Box of 2 Cartons containing 10 vials each. (20 total vials) NDC 65219-281-08 10 mL Single-Dose Vial with rubber stopper.
281205 NDC 65219-281-15 Packaged in a Box of 2 Cartons containing 10 vials each. (20 total vials) NDC 65219-281-05 15 mL Single-Dose Vial with rubber stopper.
"],"spl_medguide_table":["GBCAs like Gadobutrol injection may cause serious side effects including death, coma, encephalopathy, and seizures when it is given intrathecally (injection given into the spinal canal). It is not known if Gadobutrol injection is safe and effective with intrathecal use. Gadobutrol injection is not approved for this use.Gadobutrol injection contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years).It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.Rarely, patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium.There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance. Gadolinium stays in the body the least after Dotarem, Gadobutrol injection, or ProHance.People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive gadobutrol injection.Gadobutrol injection is a prescription medicine called a gadolinium-based contrast agent (GBCA). Gadobutrol injection, like other GBCAs, is injected into your vein and used with a magnetic resonance imaging (MRI) scanner.An MRI exam with a GBCA, including gadobutrol injection, helps your doctor to see problems better than an MRI exam without a GBCA.Your doctor has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam.have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.are pregnant or plan to become pregnant. It is not known if gadobutrol injection can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as gadobutrol injection is received during pregnancy.have kidney problems, diabetes, or high blood pressurehave had an allergic reaction to dyes (contrast agents) including GBCAsSee “What is the most important information I should know about gadobutrol injection?”Allergic reactions. Gadobutrol injection can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.A serious lung problem called acute respiratory distress syndrome (ARDS). Call your healthcare provider right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing after receiving gadobutrol injection.
Gadobutrol (GAD oh BUE trol) Injection Injection, for intravenous use
What is the most important information I should know about gadobutrol injection?
•••••••
What is gadobutrol injection?
•••
Do not receive gadobutrol injection if you have had a severe allergic reaction to gadobutrol injection.
Before receiving gadobutrol injection, tell your healthcare provider about all your medical conditions, including if you:
••••
What are the possible side effects of gadobutrol injection?
•••
The most common side effects of gadobutrol injection include: headache, nausea, and dizziness.These are not all the possible side effects of gadobutrol injection.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of gadobutrol injection.Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about gadobutrol injection that is written for health professionals.
What are the ingredients in gadobutrol injection?Active ingredient: gadobutrolInactive ingredients: calcobutrol sodium, tromethamine, hydrochloric acid (for pH adjustment) and water for injectionManufactured for:Lake Zurich, IL 60047www.fresenius-kabi.com/usFor more information, call Fresenius Kabi USA, LLC at 1-800-551-7176 Product of China451778C
"],"mechanism_of_action":["12.1 Mechanism of Action In MRI, visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with: • Differences in proton density • Differences of the spin-lattice or longitudinal relaxation times (T 1 ) • Differences in the spin-spin or transverse relaxation time (T 2 ) When placed in a magnetic field, gadobutrol shortens the T 1 and T 2 relaxation times. The extent of decrease of T 1 and T 2 relaxation times, and therefore the amount of signal enhancement obtained from gadobutrol, is based upon several factors including the concentration of gadobutrol in the tissue, the field strength of the MRI system, and the relative ratio of the longitudinal and transverse relaxation times. At the recommended dose, the T 1 shortening effect is observed with greatest sensitivity in T 1 -weighted magnetic resonance sequences. In T 2 *-weighted sequences the induction of local magnetic field inhomogeneities by the large magnetic moment of gadolinium and at high concentrations (during bolus injection) leads to a signal decrease."],"recent_major_changes":["Warnings and Precautions, Acute Respiratory Distress Syndrome ( 5.4 ) 3/2025"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action In MRI, visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with: • Differences in proton density • Differences of the spin-lattice or longitudinal relaxation times (T 1 ) • Differences in the spin-spin or transverse relaxation time (T 2 ) When placed in a magnetic field, gadobutrol shortens the T 1 and T 2 relaxation times. The extent of decrease of T 1 and T 2 relaxation times, and therefore the amount of signal enhancement obtained from gadobutrol, is based upon several factors including the concentration of gadobutrol in the tissue, the field strength of the MRI system, and the relative ratio of the longitudinal and transverse relaxation times. At the recommended dose, the T 1 shortening effect is observed with greatest sensitivity in T 1 -weighted magnetic resonance sequences. In T 2 *-weighted sequences the induction of local magnetic field inhomogeneities by the large magnetic moment of gadolinium and at high concentrations (during bolus injection) leads to a signal decrease. 12.2 Pharmacodynamics Gadobutrol leads to distinct shortening of the relaxation times even in low concentrations. At pH 7, 37°C and 1.5 T, the relaxivity (r 1 ) - determined from the influence on the relaxation times (T 1 ) of protons in plasma - is 5.2 L/(mmol·sec) and the relaxivity (r 2 ) - determined from the influence on the relaxation times (T 2 ) - is 6.1 L/(mmol·sec). These relaxivities display only slight dependence on the strength of the magnetic field. The T 1 shortening effect of paramagnetic contrast agents is dependent on concentration and r 1 relaxivity (see Table 3 ). This may improve tissue visualization. Table 3: Relaxivity (r 1 ) of Gadolinium Chelates at 1.5 T r 1 relaxivity in plasma at 37°C Gadolinium-Chelate r 1 (L·mmol -1 ·s -1 ) Gadobenate 6.3 Gadobutrol 5.2 Gadodiamide 4.3 Gadofosveset 16 Gadopentetate 4.1 Gadoterate 3.6 Gadoteridol 4.1 Gadoversetamide 4.7 Gadoxetate 6.9 Compared to 0.5 molar gadolinium-based contrast agents, the higher concentration of gadobutrol injection results in half the volume of administration and a more compact contrast bolus injection. At the site of imaging, the relative height and width of the time intensity curve for gadobutrol injection varies as a function of imaging location and multiple patient, injection, and device-specific factors. Gadobutrol is a water-soluble, hydrophilic compound with a partition coefficient between n-butanol and buffer at pH 7.6 of about 0.006. 12.3 Pharmacokinetics Distribution After intravenous administration, gadobutrol is rapidly distributed in the extracellular space. After a gadobutrol dose of 0.1 mmol/kg body weight, an average level of 0.59 mmol gadobutrol/L was measured in plasma 2 minutes after the injection and 0.3 mmol gadobutrol/L 60 minutes after the injection. Gadobutrol does not display any particular protein binding. Following GBCA administration, gadolinium is present for months or years in brain, bone, skin, and other organs [see Warnings and Precautions ( 5.5 )] . Metabolism Gadobutrol is not metabolized. Elimination Values for AUC, body weight normalized plasma clearance and half-life are given in Table 4 , below. Gadobutrol is excreted in an unchanged form via the kidneys. In healthy subjects, renal clearance of gadobutrol is 1.1 to 1.7 mL/(min∙kg) and thus comparable to the renal clearance of inulin, confirming that gadobutrol is eliminated by glomerular filtration. Within two hours after intravenous administration more than 50% and within 12 hours more than 90% of the given dose is eliminated via the urine. Extra-renal elimination is negligible. Specific Populations Gender Gender has no clinically relevant effect on the pharmacokinetics of gadobutrol. Geriatric A single intravenous dose of 0.1 mmol/kg gadobutrol injection was administered to 15 elderly and 16 non-elderly subjects. AUC was slightly higher and clearance slightly lower in elderly subjects as compared to non-elderly subjects [see Use in Specific Populations ( 8.5 )] . Pediatric The pharmacokinetics of gadobutrol were evaluated in two studies in a total of 130 patients age 2 to less than 18 years and in 43 patients less than 2 years of age (including term neonates). Patients received a single intravenous dose of 0.1 mmol/kg of gadobutrol injection. The pharmacokinetic profile of gadobutrol in pediatric patients is similar to that in adults, resulting in similar values for AUC, body weight normalized plasma clearance, as well as elimination half-life. Approximately 99% (median value) of the dose was recovered in urine within 6 hours (this information was derived from the 2 to less than 18 year old age group). Table 4: Pharmacokinetics by Age Group (Median [Range]) 0 to < 2 years 2 to 6 years 7 to 11 years 12 to < 18 years Adults N=43 N=45 N=39 N=46 N=93 AUC (µmolxh/L) 781 [513, 1,891] 846 [412, 1,331] 1,025 [623, 2,285] 1,237 [946, 2,211] 1,072 [667, 1,992] CL (L/h/kg) 0.128 [0.053, 0.195] 0.119 [0.08, 0.215] 0.099 [0.043, 0.165] 0.081 [0.046, 0.103] 0.094 [0.051, 0.150] t 1/2 (h) 2.91 [1.60, 12.4] 1.91 [1.04, 2.70] 1.66 [0.91, 2.71] 1.68 [1.31, 2.48] 1.80 [1.20, 6.55] C 20 (µmol/L) 367 [280, 427] 421 [369, 673] 462 [392, 760] 511 [387, 1,077] 441 [281, 829] Renal Impairment In patients with impaired renal function, the serum half-life of gadobutrol is prolonged and correlated with the reduction in creatinine clearance. After intravenous injection of 0.1 mmol gadobutrol/kg body weight, the elimination half-life was 5.8 ± 2.4 hours in mild to moderately impaired patients (80 > CL CR > 30 mL/min) and 17.6 ± 6.2 hours in severely impaired patients not on dialysis (CL CR < 30 mL/min). The mean AUC of gadobutrol in patients with normal renal function was 1.1 ± 0.1 mmol∙h/L, compared to 4.0 ± 1.8 mmol∙h/L in patients with mild to moderate renal impairment and 11.5 ± 4.3 mmol∙h/L in patients with severe renal impairment. Complete recovery in the urine was seen in patients with mild or moderate renal impairment within 72 hours. In patients with severely impaired renal function about 80% of the administered dose was recovered in the urine within 5 days. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of gadobutrol injection in order to enhance the contrast agent’s elimination. Sixty-eight percent (68%) of gadobutrol is removed from the body after the first dialysis, 94% after the second dialysis, and 98% after the third dialysis session. [see Warnings and Precautions ( 5.2 ) and Use in Specific Populations ( 8.6 ).]"],"indications_and_usage":["1 INDICATIONS AND USAGE Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): • To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1 ) • To assess the presence and extent of malignant breast disease in adult patients ( 1.2 ) • To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3 ) • To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). ( 1.4 ). 1.1 Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) Gadobutrol injection is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients, including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. 1.2 MRI of the Breast Gadobutrol injection is indicated for use with MRI in adult patients to assess the presence and extent of malignant breast disease. 1.3 Magnetic Resonance Angiography (MRA) Gadobutrol injection is indicated for use in magnetic resonance angiography (MRA) in adult and pediatric patients, including term neonates, to evaluate known or suspected supra-aortic or renal artery disease. 1.4 Cardiac MRI Gadobutrol injection is indicated for use in cardiac MRI (CMRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD)."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Hypersensitivity Reactions: Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred. Monitor patients closely during and after administration of gadobutrol injection. ( 5.3 ) • Acute Respiratory Distress Syndrome: For Patients demonstrating respiratory distress after administration, assess oxygen requirement and monitor for worsening respiratory function. ( 5.4 ) • Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs. ( 5.5 ) 5.1 Risk Associated with Intrathecal Use Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of Gadobutrol injection have not been established with intrathecal use. Gadobutrol injection is not approved for intrathecal use [see Dosage and Administration ( 2.2 )] . 5.2 Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of gadobutrol injection among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ) as well as patients with acute kidney injury. The risk appears lower for patients with chronic, moderate kidney disease (GFR 30 to 59 mL/min/1.73m 2 ) and little, if any, for patients with chronic, mild kidney disease (GFR 60 to 89 mL/min/1.73m 2 ). NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Report any diagnosis of NSF following gadobutrol injection administration to Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA (1-800-FDA-1088 or www.fda.gov/medwatch). Screen patients for acute kidney injury and other conditions that may reduce renal function. Features of acute kidney injury consist of rapid (over hours to days) and usually reversible decrease in kidney function, commonly in the setting of surgery, severe infection, injury or drug-induced kidney toxicity. Serum creatinine levels and estimated GFR may not reliably assess renal function in the setting of acute kidney injury. For patients at risk for chronically reduced renal function (for example, age > 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing. Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA and degree of renal impairment at the time of exposure. Record the specific GBCA and the dose administered to a patient. For patients at highest risk for NSF, do not exceed the recommended gadobutrol injection dose and allow a sufficient period of time for elimination of the drug prior to re-administration. For patients receiving hemodialysis, consider the prompt initiation of hemodialysis following the administration of a GBCA in order to enhance the contrast agent’s elimination [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12.3 )]. The usefulness of hemodialysis in the prevention of NSF is unknown [see Clinical Pharmacology ( 12.3 )]. 5.3 Hypersensitivity Reactions Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following gadobutrol injection administration [see Adverse Reactions ( 6 )] . • Before gadobutrol injection administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to gadobutrol injection. • Administer gadobutrol injection only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation. Most hypersensitivity reactions to gadobutrol injection have occurred within half an hour after administration. Delayed reactions can occur up to several days after administration. Observe patients for signs and symptoms of hypersensitivity reactions during and following gadobutrol injection administration. 5.4 Acute Respiratory Distress Syndrome Acute respiratory distress syndrome (ARDS) has been reported in patients administered gadobutrol injection and may be characterized by severe hypoxemia requiring oxygen support and mechanical ventilation. These manifestations may resemble an immediate hypersensitivity reaction with onset of respiratory distress within <30 minutes to 24 hours after gadobutrol injection administration. For patients demonstrating respiratory distress after gadobutrol injection administration, assess oxygen requirement and monitor for worsening respiratory function. 5.5 Gadolinium Retention Gadolinium is retained for months or years in several organs. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (for example, brain, skin, kidney, liver, and spleen). The duration of retention also varies by tissue and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, gadolinium retention varies among the linear agents with Omniscan (gadodiamide) and Optimark (gadoversetamide) causing greater retention than other linear agents [Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), MultiHance (gadobenate dimeglumine)]. Retention is lowest and similar among the macrocyclic GBCAs [Dotarem (gadoterate meglumine), Gadobutrol injection (gadobutrol), ProHance (gadoteridol)]. Consequences of gadolinium retention in the brain have not been established. Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function [see Warnings and Precautions ( 5.2 )] . There are rare reports of pathologic skin changes in patients with normal renal function. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention [see Adverse Reactions ( 6.2 )] . While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent when choosing a GBCA for these patients. Minimize repetitive GBCA imaging studies particularly closely spaced studies, when possible. 5.6 Acute Kidney Injury In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses. 5.7 Extravasation and Injection Site Reactions Ensure catheter and venous patency before the injection of gadobutrol injection. Extravasation into tissues during gadobutrol injection administration may result in moderate irritation [see Nonclinical Toxicology ( 13.2 )] . 5.8 Overestimation of Extent of Malignant Disease in MRI of the Breast Gadobutrol injection MRI of the breast overestimated the histologically confirmed extent of malignancy in the diseased breast in up to 50% of the patients [see Clinical Studies ( 14.2 )]. 5.9 Low Sensitivity for Significant Arterial Stenosis The performance of gadobutrol injection MRA for detecting arterial segments with significant stenosis (>50% renal, >70% supra-aortic) has not been shown to exceed 55%. Therefore, a negative MRA study alone should not be used to rule out significant stenosis [see Clinical Studies ( 14.3 )]."],"clinical_studies_table":["
Table 5: Primary Endpoint Visualization Scoring System
ScoreVisualization Characteristics
Contrast EnhancementBorder DelineationInternal Morphology
1NoneNonePoorly visible
2WeakModerateModerately visible
3ClearClear but incompleteSufficiently visible
4Clear and brightClear and completeN/A
","
Table 6: Visualization Endpoint Results of Central Nervous System Adult MRI Studies with 0.1 mmol/kg Gadobutrol Injection
EndpointStudy A N=336Study B N=321
Pre-contrastPairedDifferenceDifference of means = (paired mean) – (pre-contrast mean)Pre-contrastPairedDifference
Contrast Enhancement0.972.261.29p<0.0010.932.861.94
Border Delineation1.982.580.601.922.941.02
Internal Morphology1.321.930.601.572.350.78
Average # Lesions Detected8.088.250.17Did not meet noninferiority margin of -0.352.652.970.32Met noninferiority margin of -0.35
","
Table 7: Primary Endpoint Visualization Categorical Improvement for Average Reader
Study A N=336Study B N=321
Endpoint Categorical Improvement (Paired – Pre-Contrast) %Categorical Improvement (Paired – Pre-Contrast) %
≤ 0> 0 to < 11 to < 2≥ 2≤ 0> 0 to < 11 to < 2≥ 2
Contrast Enhancement1305513363457
Border Delineation773181538515
Internal Morphology479170561331
","
Table 8: Sensitivity of Gadobutrol Injection BMR for Detection of Malignant Breast Disease
Study 1Study 2
Sensitivity (%)N=388 PatientsSensitivity (%)N=390 Patients
ReaderBMRBMR + XRMGadobutrol Injection BMRGadobutrol Injection BMR+XRMReaderBMRBMR + XRMGadobutrol Injection BMRGadobutrol Injection BMR +XRM
137718384473838790
249768083557818990
363758787655808688
","
Table 9: Specificity of Gadobutrol Injection BMR in Non-Malignant Breasts
Study 1Study 2
Specificity (%)N=372 PatientsSpecificity (%)N=367 Patients
ReaderGadobutrol Injection BMRLower Limit95% CIReaderGadobutrol Injection BMRLower Limit95% CI
1868249289
2959358480
3898568379
","
Table 10: Visualization, Sensitivity, Specificity
STUDY C: SUPRA-AORTIC ARTERIES (457 patients)Performance at the segment level9,597Number of segments varied between readers; number for majority-reader shown.segments of which 158 were positive for stenosis by SoRStandard of Reference based on aggregate interpretation of three central CTA readers.
VISUALIZATION (%)SENSITIVITY (%)SPECIFICITY (%)
READERGADMRAToF MRAGAD - ToF(CI95.1/95% (Study C/D) confidence interval for two-sided comparison.)GAD MRAToF MRAGAD - ToF (CI90.1/90% (Study C/D) confidence interval for one-sided comparison against non-inferiority margin of -7.5. GAD MRA = Post-contrast Gadobutrol Injection Magnetic Resonance Angiography, ToF = Non-contrast 2D-Time of Flight.)GAD MRAToF MRAGAD - ToF (CI)
1882464(61, 67)60546(-4, 14)926230(29, 32)
2957520(18, 21)60546(-3, 14)958510 (9, 11)
3978215(13, 17)58553(-4, 11)97898(7, 9)
STUDY D: RENAL ARTERIES (292 patients)Performance at the segment level1,752* segments of which 133* were positive for stenosis by SoR†
4988216(13, 20)52511(-9, 11)948311(9, 14)
5967224(21, 28)543915(6, 24)958510 (8, 12)
6967817(14, 21)53503(-6, 12)948113(11, 16)
","
Table 11: Percent of Patients with Range ≥ 30%, ≥ 50%, ≥ 70% for Measurement of Stenoses and Normal Vessel Diameters
Internal CarotidProximal Main Renal
N≥ 30% ≥ 50% ≥ 70% N≥ 30%≥ 50%≥ 70%
CTA4564011429259339
ToF MRA4435522927044229
Gadobutrol Injection MRA4544713428634144
","
Table 12: Sensitivity (%) of Gadobutrol Injection CMRI for Detection of CAD in Patients with Maximum Stenosis* of ≥50% and ≥70%
Study E Study F
≥50% N=141 ≥70% N=108 ≥50% N=150 ≥70% N=105
Reader 1** 77 (69, 83)*** 90 (83, 95) 65 (57, 72) 77 (68, 85)
Reader 2** 65 (57, 73) 80 (71, 87) 56 (48, 64) 71 (62, 80)
Reader 3** 65 (56, 72) 79 (70, 86) 61 (53, 69) 76 (67, 84)
","
Table 13: Specificity (%) of Gadobutrol Injection CMRI for Exclusion of CAD in Patients with Maximum Stenosis* of ≥50% and ≥70%
Study E Study F
≥50% N=235 ≥70% N=268 ≥50% N=239 ≥70% N=283
Reader 1** 85 (80, 89)*** 83 (78, 87) 85 (80, 90) 82 (77, 86)
Reader 2** 92 (88, 95) 91 (87, 94) 89 (84, 92) 87 (83, 91)
Reader 3** 92 (88, 95) 91 (87, 94) 90 (85, 93) 87 (82, 91)
","
Table 14: Gadobutrol Injection-CMRI Detection of CAD in Patients with Maximum Stenosis* between 50% and < 70%
Study E (n=33) Study F (n=45)
Gadobutrol Injection-CMRI positive Gadobutrol Injection-CMRI positive
Reader 1** 11 (33%) 16 (35%)
Reader 2** 5(15%) 9 (20%)
Reader 3** 6(18%) 12 (26%)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity studies of gadobutrol have been conducted. Gadobutrol was not mutagenic in in vitro reverse mutation tests in bacteria, in the HGPRT (hypoxanthine-guanine phosphoribosyl transferase) test using cultured Chinese hamster V79 cells, or in chromosome aberration tests in human peripheral blood lymphocytes, and was negative in an in vivo micronucleus test in mice after intravenous injection of 0.5 mmol/kg. Gadobutrol had no effect on fertility and general reproductive performance of male and female rats when given in doses 12.2 times the human equivalent dose (based on body surface area). 13.2 Animal Toxicology and/or Pharmacology Local intolerance reactions, including moderate irritation associated with infiltration of inflammatory cells was observed after paravenous administration to rabbits, suggesting the possibility of occurrence of local irritation if the contrast medium leaks around veins in a clinical setting [see Warnings and Precautions ( 5.7 )]."],"pharmacodynamics_table":["
Table 3: Relaxivity (r1) of Gadolinium Chelates at 1.5 T
r1 relaxivity in plasma at 37°C
Gadolinium-Chelate r1 (L·mmol -1 ·s-1)
Gadobenate6.3
Gadobutrol5.2
Gadodiamide4.3
Gadofosveset16
Gadopentetate4.1
Gadoterate3.6
Gadoteridol4.1
Gadoversetamide4.7
Gadoxetate6.9
"],"pharmacokinetics_table":["
Table 4: Pharmacokinetics by Age Group (Median [Range])
0 to < 2 years2 to 6 years7 to 11 years12 to < 18 yearsAdults
N=43N=45N=39N=46N=93
AUC (µmolxh/L)781[513, 1,891]846[412, 1,331]1,025[623, 2,285]1,237[946, 2,211]1,072[667, 1,992]
CL (L/h/kg)0.128[0.053, 0.195]0.119[0.08, 0.215]0.099[0.043, 0.165]0.081[0.046, 0.103]0.094[0.051, 0.150]
t1/2 (h)2.91[1.60, 12.4]1.91[1.04, 2.70]1.66[0.91, 2.71]1.68[1.31, 2.48]1.80[1.20, 6.55]
C20 (µmol/L)367[280, 427]421[369, 673]462[392, 760]511[387, 1,077]441[281, 829]
"],"adverse_reactions_table":["
Table 2: Adverse Reactions
ReactionRate (%)n=7,713
Headache1.7
Nausea1.2
Dizziness0.5
Dysgeusia0.4
Feeling Hot0.4
Injection site reactions0.4
Vomiting0.4
Rash (includes generalized, macular, papular, pruritic)0.3
Erythema0.2
Paresthesia0.2
Pruritus (includes generalized)0.2
Dyspnea0.1
Urticaria0.1
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION • Advise the patient to read the FDA-approved patient labeling (Medication Guide). Nephrogenic Systemic Fibrosis Instruct patients to inform their physician if they: • Have a history of kidney disease and/or liver disease, or • Have recently received a GBCA GBCAs increase the risk of NSF among patients with impaired elimination of drugs. To counsel patients at risk of NSF: • Describe the clinical manifestation of NSF • Describe procedures to screen for the detection of renal impairment Instruct the patients to contact their physician if they develop signs or symptoms of NSF following gadobutrol injection administration, such as burning, itching, swelling, scaling, hardening and tightening of the skin; red or dark patches on the skin; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; pain in the hip bones or ribs; or muscle weakness. Common Adverse Reactions Inform patients that they may experience: • Reactions along the venous injection site, such as mild and transient burning or pain or feeling of warmth or coldness at the injection site • Side effects of headache, nausea, abnormal taste and feeling hot Acute Respiratory Distress Syndrome • Advise patients that acute respiratory distress syndrome (ARDS) has occurred with gadobutrol injection. Inform patients on the symptoms of the observed ARDS cases, and instruct patients to inform their healthcare provider if they experience these symptoms [see Warnings and Precautions ( 5.4 )] . General Precautions Gadolinium Retention • Advise patients that gadolinium is retained for months or years in brain, bone, skin, and other organs in patients with normal renal function. The clinical consequences of retention are unknown. Retention depends on multiple factors and is greater following administration of linear GBCAs than following administration of macrocyclic GBCAs [see Warnings and Precautions ( 5.5 )]. Instruct patients receiving gadobutrol injection to inform their physician if they: • Are pregnant or breastfeeding • Have a history of allergic reaction to contrast media, bronchial asthma or allergic respiratory disorder Manufactured for: Lake Zurich, IL 60047 www.fresenius-kabi.com/us Product of China Revised: May 2025 451778C 26AUF04 gadob-img-01.jpg"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Recommended dose for adults and pediatric patients (including term neonates) is 0.1 mL/kg body weight ( 2.1 ) • Administer as an intravenous bolus injection ( 2.2 ) • Follow injection with a normal saline flush ( 2.2 ) 2.1 Recommended Dose The recommended dose of gadobutrol injection for adult and pediatric patients (including term neonates) is 0.1 mL/kg body weight (0.1 mmol/kg). Refer to Table 1 to determine the volume to be administered. Table 1: Volume of Gadobutrol Injection by Body Weight* Body Weight (kg) Volume to be Administered (mL) 2.5 0.25 5 0.5 10 1 15 1.5 20 2 25 2.5 30 3 35 3.5 40 4 45 4.5 50 5 60 6 70 7 80 8 90 9 100 10 110 11 120 12 130 13 140 14 *for Cardiac MRI, the dose is divided into 2 separate, equal injections 2.2 Administration Guidelines • Gadobutrol injection is formulated at a higher concentration (1 mmol/mL) compared to certain other gadolinium based contrast agents, resulting in a lower volume of administration. Use Table 1 to determine the volume to be administered. • Use sterile technique when preparing and administering gadobutrol injection. MRI of the Central Nervous System • Administer gadobutrol injection as an intravenous injection, manually or by power injector, at a flow rate of approximately 2 mL/second. • Follow gadobutrol injection with a normal saline flush to ensure complete administration of the contrast. • Post contrast MRI can commence immediately following contrast administration. MRI of the Breast • Administer gadobutrol injection as an intravenous bolus by power injector, followed by a normal saline flush to ensure complete administration of the contrast. • Start image acquisition following contrast administration and then repeat sequentially to determine peak intensity and wash-out. MR Angiography Image acquisition should coincide with peak arterial concentration, which varies among patients. Adults • Administer gadobutrol injection by power injector, at a flow rate of approximately 1.5 mL/second, followed by a 30 mL normal saline flush at the same rate to ensure complete administration of the contrast. Pediatric patients • Administer gadobutrol injection by power injector or manually, followed by a normal saline flush to ensure complete administration of the contrast. Cardiac MRI • Administer gadobutrol injection through a separate intravenous line in the contralateral arm if concomitantly providing a continuous infusion of a pharmacologic stress agent. • Administer gadobutrol injection as two (2) separate bolus injections: 0.05 mL/kg (0.05 mmol/kg) body weight at peak pharmacologic stress followed by 0.05 mL/kg (0.05 mmol/kg) body weight at rest. • Administer gadobutrol injection via a power injector at a flow rate of approximately 4 mL/second and follow each injection with a normal saline flush of 20 mL at the same flow rate. 2.3 Drug Handling • Visually inspect gadobutrol injection for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored, if particulate matter is present or if the container appears damaged. • Do not mix gadobutrol injection with other medications and do not administer gadobutrol injection in the same intravenous line simultaneously with other medications because of the potential for chemical incompatibility. Vials • Draw gadobutrol injection into the syringe immediately before use. • Do not pierce the rubber stopper more than once. Discard any unused vial contents."],"spl_product_data_elements":["Gadobutrol Gadobutrol Gadobutrol Gadolinium Cation (3+) Tromethamine Calcobutrol Sodium Hydrochloric Acid Water"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Gadobutrol injection is a sterile, clear, and colorless to pale yellow solution for injection containing 604.72 mg gadobutrol per mL (equivalent to 1 mmol gadobutrol/mL) supplied in single-dose vials. Gadobutrol injection contains 604.72 mg gadobutrol/mL (equivalent to 1 mmol gadobutrol/mL) and is available in vials ( 3 )"],"clinical_pharmacology_table":["
Table 3: Relaxivity (r1) of Gadolinium Chelates at 1.5 T
r1 relaxivity in plasma at 37°C
Gadolinium-Chelate r1 (L·mmol -1 ·s-1)
Gadobenate6.3
Gadobutrol5.2
Gadodiamide4.3
Gadofosveset16
Gadopentetate4.1
Gadoterate3.6
Gadoteridol4.1
Gadoversetamide4.7
Gadoxetate6.9
","
Table 4: Pharmacokinetics by Age Group (Median [Range])
0 to < 2 years2 to 6 years7 to 11 years12 to < 18 yearsAdults
N=43N=45N=39N=46N=93
AUC (µmolxh/L)781[513, 1,891]846[412, 1,331]1,025[623, 2,285]1,237[946, 2,211]1,072[667, 1,992]
CL (L/h/kg)0.128[0.053, 0.195]0.119[0.08, 0.215]0.099[0.043, 0.165]0.081[0.046, 0.103]0.094[0.051, 0.150]
t1/2 (h)2.91[1.60, 12.4]1.91[1.04, 2.70]1.66[0.91, 2.71]1.68[1.31, 2.48]1.80[1.20, 6.55]
C20 (µmol/L)367[280, 427]421[369, 673]462[392, 760]511[387, 1,077]441[281, 829]
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: Use only if imaging is essential during pregnancy and cannot be delayed. ( 8.1 ) 8.1 Pregnancy Risk Summary GBCAs cross the placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive (see Data ) . In animal reproduction studies, although teratogenicity was not observed, embryolethality was observed in monkeys, rabbits and rats receiving intravenous gadobutrol during organogenesis at doses 8 times and above the recommended human dose. Retardation of embryonal development was observed in rabbits and rats receiving intravenous gadobutrol during organogenesis at doses 8 and 12 times, respectively, the recommended human dose (see Data ). Because of the potential risks of gadolinium to the fetus, use gadobutrol injection only if imaging is essential during pregnancy and cannot be delayed. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and is 15% to 20%, respectively. Data Human Data Contrast enhancement is visualized in the placenta and fetal tissues after maternal GBCA administration. Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported a clear association between GBCAs and adverse effects in the exposed neonates. However, a retrospective cohort study, comparing pregnant women who had a GBCA MRI to pregnant women who did not have an MRI, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include a lack of comparison with non-contrast MRI and lack of information about the maternal indication for MRI. Overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy. Animal Data Gadolinium Retention GBCAs administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. GBCAs administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one month postnatal age. Reproductive Toxicology Embryolethality was observed when gadobutrol was administered intravenously to monkeys during organogenesis at doses 8 times the recommended single human dose (based on body surface area); gadobutrol was not maternally toxic or teratogenic at this dose. Embryolethality and retardation of embryonal development also occurred in pregnant rats receiving maternally toxic doses of gadobutrol (≥ 7.5 mmol/kg body weight; equivalent to 12 times the human dose based on body surface area) and in pregnant rabbits (≥ 2.5 mmol/kg body weight; equivalent to 8 times the recommended human dose based on body surface area). In rabbits, this finding occurred without evidence of pronounced maternal toxicity and with minimal placental transfer (0.01% of the administered dose detected in the fetuses). Because pregnant animals received repeated daily doses of gadobutrol injection, their overall exposure was significantly higher than that achieved with the standard single dose administered to humans. 8.2 Lactation Risk Summary There are no data on the presence of gadobutrol in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01% to 0.04% of the maternal gadolinium dose is present in breast milk and there is limited GBCA gastrointestinal absorption in the breast-fed infant. Gadobutrol is present in rat milk (see Data ). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for gadobutrol injection and any potential adverse effects on the breastfed infant from gadobutrol injection or from the underlying maternal condition. Data In lactating rats receiving 0.5 mmol/kg of intravenous [ 153 Gd]-gadobutrol, 0.01% of the total administered radioactivity was transferred to the pup via maternal milk within 3 hours after administration, and the gastrointestinal absorption is poor (approximately 5% of the dose orally administered was excreted in the urine). 8.4 Pediatric Use The safety and effectiveness of gadobutrol injection have been established in pediatric patients, including term neonates, for use with MRI to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system and for use in MRA to evaluate known or suspected supra-aortic or renal artery disease. Use of gadobutrol injection in these indications is supported by adequate and well-controlled studies in adults and supportive imaging data in two studies in 135 patients 2 to less than 18 years of age and 44 patients less than 2 years of age with CNS and non-CNS lesions, and pharmacokinetic data in 130 patients 2 to less than 18 years of age and 43 patients less than 2 years of age, including term neonates [ see Clinical Pharmacology ( 12.3 ), and Clinical Studies ( 14.1 ) ]. The frequency, type, and severity of adverse reactions in pediatric patients were similar to adverse reactions in adults [see Adverse Reactions ( 6.1 )] . No dose adjustment according to age is necessary in pediatric patients [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.3 ), and Clinical Studies ( 14.1 )] . The safety and effectiveness of gadobutrol injection have not been established in preterm neonates for any indication or in pediatric patients of any age for use with MRI to assess the presence and extent of malignant breast disease, or for use in CMRI to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in patients with known or suspected coronary artery disease (CAD). NSF Risk No case of NSF associated with gadobutrol injection or any other GBCA has been identified in pediatric patients ages 6 years and younger. Pharmacokinetic studies suggest that clearance of gadobutrol injection is similar in pediatric patients and adults, including pediatric patients age younger than 2 years. No increased risk factor for NSF has been identified in juvenile animal studies of gadobutrol. Normal estimated GFR (eGFR) is around 30 mL/min/1.73m 2 at birth and increases to mature levels around 1 year of age, reflecting growth in both glomerular function and relative body surface area. Clinical studies in pediatric patients younger than 1 year of age have been conducted in patients with the following minimum eGFR: 31 mL/min/1.73m 2 (age 2 to 7 days), 38 mL/min/1.73m 2 (age 8 to 28 days), 62 mL/min/1.73m 2 (age 1 to 6 months), and 83 mL/min/1.73m 2 (age 6 to 12 months). Juvenile Animal Data Single and repeat-dose toxicity studies in neonatal and juvenile rats did not reveal findings suggestive of a specific risk for use in pediatric patients including term neonates and infants. 8.5 Geriatric Use In clinical studies of gadobutrol injection, 1,377 patients were 65 years of age and over, while 104 patients were 80 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, use of gadobutrol injection in elderly patients should be cautious, reflecting the greater frequency of impaired renal function and concomitant disease or other drug therapy. No dose adjustment according to age is necessary in this population. 8.6 Renal Impairment Prior to administration of gadobutrol injection, screen all patients for renal dysfunction by obtaining a history and/or laboratory tests [see Warnings and Precautions ( 5.2 )] . No dosage adjustment is recommended for patients with renal impairment. Gadobutrol can be removed from the body by hemodialysis [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["
Table 1: Volume of Gadobutrol Injection by Body Weight*
Body Weight (kg)Volume to be Administered (mL)
2.50.25
50.5
101
151.5
202
252.5
303
353.5
404
454.5
505
606
707
808
909
10010
11011
12012
13013
14014
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Local intolerance reactions, including moderate irritation associated with infiltration of inflammatory cells was observed after paravenous administration to rabbits, suggesting the possibility of occurrence of local irritation if the contrast medium leaks around veins in a clinical setting [see Warnings and Precautions ( 5.7 )]."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL – 2 mmol/2 mL - Carton Dose: 0.1 mL/kg 3 x 2 mL NDC 65219- 281 -02 Rx only Gadobutrol Injection 2 mmol/2 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vials Discard Unused Portion. Sterile Solution gadob-label-01.jpg","PRINCIPAL DISPLAY PANEL – 2 mmol/2 mL – Vial Label Dose: 0.1 mL/kg 2 mL NDC 65219- 281 -00 Rx only Gadobutrol Injection 2 mmol/2 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vial Discard Unused Portion. Sterile Solution gadob-label-02.jpg","PRINCIPAL DISPLAY PANEL – 7.5 mmol/7.5 mL - Carton Dose: 0.1 mL/kg 10 x 7.5 mL NDC 65219- 281 -07 Rx only Gadobutrol Injection 7.5 mmol/7.5 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vials Discard Unused Portion. Sterile Solution gadob-label-03.jpg","PRINCIPAL DISPLAY PANEL – 7.5 mmol/7.5 mL – Vial Label Dose: 0.1 mL/kg 7.5 mL NDC 65219- 281 -03 Rx only Gadobutrol Injection 7.5 mmol/7.5 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vial Discard Unused Portion. Sterile Solution gadob-label-04.jpg","PRINCIPAL DISPLAY PANEL – 10 mmol/10 mL - Carton Dose: 0.1 mL/kg 10 x 10 mL NDC 65219- 281 -10 Rx only Gadobutrol Injection 10 mmol/10 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vials Discard Unused Portion. Sterile Solution gadob-label-05.jpg","PRINCIPAL DISPLAY PANEL – 10 mmol/10 mL – Vial Label Dose: 0.1 mL/kg 10 mL NDC 65219- 281 -08 Rx only Gadobutrol Injection 10 mmol/10 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vials Discard Unused Portion. Sterile Solution gadob-label-06.jpg","PRINCIPAL DISPLAY PANEL – 15 mmol/15 mL - Carton Dose: 0.1 mL/kg 10 x 15 mL NDC 65219- 281 -15 Rx only Gadobutrol Injection 15 mmol/15 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vials Discard Unused Portion. Sterile Solution gadob-label-07.jpg","PRINCIPAL DISPLAY PANEL – 15 mmol/15 mL – Vial Label Dose: 0.1 mL/kg 15 mL NDC 65219- 281 -05 Rx only Gadobutrol Injection 15 mmol/15 mL (1 mmol/mL) For Intravenous Administration Single-Dose Vial Discard Unused Portion. Sterile Solution gadob-label-08.jpg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity studies of gadobutrol have been conducted. Gadobutrol was not mutagenic in in vitro reverse mutation tests in bacteria, in the HGPRT (hypoxanthine-guanine phosphoribosyl transferase) test using cultured Chinese hamster V79 cells, or in chromosome aberration tests in human peripheral blood lymphocytes, and was negative in an in vivo micronucleus test in mice after intravenous injection of 0.5 mmol/kg. Gadobutrol had no effect on fertility and general reproductive performance of male and female rats when given in doses 12.2 times the human equivalent dose (based on body surface area)."]},"tags":[{"label":"Gadolinium-based Contrast Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"V08CA09","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Magnetic resonance imaging","category":"indication"},{"label":"Bayer Hlthcare","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Contrast Media","category":"pharmacology"},{"label":"Diagnostic Uses of Chemicals","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadobutrol injection is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of drugs. Avoid use of gadobutrol injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. • The risk for NSF appears highest among patients with: o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or o Acute kidney injury. • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. • For patients at highest risk for NSF, do not exceed the recommended gadobutrol injection dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration [see Warnings and Precautions ( 5.2 )] . WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS See full prescribing information for complete boxed warning • Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadobutrol injection is not approved for intrathecal use ( 5.1 ) • GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of drugs. Avoid use of gadobutrol injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. • The risk for NSF appears highest among patients with: o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or o Acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. ( 5.2 )."],"safetySignals":[{"llr":1925.223,"date":"","count":734,"signal":"Urticaria","source":"DrugCentral FAERS","actionTaken":"Reported 734 times (LLR=1925)"},{"llr":655.62,"date":"","count":462,"signal":"Pruritus","source":"DrugCentral FAERS","actionTaken":"Reported 462 times (LLR=656)"},{"llr":538.214,"date":"","count":499,"signal":"Vomiting","source":"DrugCentral FAERS","actionTaken":"Reported 499 times (LLR=538)"},{"llr":516.305,"date":"","count":71,"signal":"Gadolinium deposition disease","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=516)"},{"llr":491.287,"date":"","count":568,"signal":"Nausea","source":"DrugCentral FAERS","actionTaken":"Reported 568 times (LLR=491)"},{"llr":466.019,"date":"","count":91,"signal":"Contrast media reaction","source":"DrugCentral FAERS","actionTaken":"Reported 91 times (LLR=466)"},{"llr":365.131,"date":"","count":251,"signal":"Erythema","source":"DrugCentral FAERS","actionTaken":"Reported 251 times (LLR=365)"},{"llr":325.264,"date":"","count":42,"signal":"Nontherapeutic agent urine positive","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=325)"},{"llr":297.035,"date":"","count":67,"signal":"Contrast media allergy","source":"DrugCentral FAERS","actionTaken":"Reported 67 times (LLR=297)"},{"llr":281.61,"date":"","count":40,"signal":"Contrast media deposition","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=282)"},{"llr":240.003,"date":"","count":88,"signal":"Sneezing","source":"DrugCentral FAERS","actionTaken":"Reported 88 times (LLR=240)"},{"llr":234.094,"date":"","count":108,"signal":"Throat irritation","source":"DrugCentral FAERS","actionTaken":"Reported 108 times (LLR=234)"},{"llr":165.852,"date":"","count":94,"signal":"Feeling hot","source":"DrugCentral FAERS","actionTaken":"Reported 94 times (LLR=166)"},{"llr":153.122,"date":"","count":307,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 307 times (LLR=153)"},{"llr":152.434,"date":"","count":70,"signal":"Throat tightness","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=152)"}],"commonSideEffects":[{"effect":"Headache","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dizziness","drugRate":"0.5%","severity":"mild","_validated":true},{"effect":"Dysgeusia","drugRate":"0.4%","severity":"mild","_validated":true},{"effect":"Feeling Hot","drugRate":"0.4%","severity":"mild","_validated":true},{"effect":"Injection site reactions","drugRate":"0.4%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"0.4%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"0.3%","severity":"mild","_validated":true},{"effect":"Erythema","drugRate":"0.2%","severity":"mild","_validated":true},{"effect":"Paresthesia","drugRate":"0.2%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"0.2%","severity":"mild","_validated":true},{"effect":"Dyspnea","drugRate":"0.1%","severity":"mild","_validated":true},{"effect":"Urticaria","drugRate":"0.1%","severity":"mild","_validated":true},{"effect":"Hypersensitivity/anaphylactic reaction","drugRate":"reported","severity":"unknown"},{"effect":"Loss of consciousness","drugRate":"reported","severity":"unknown"},{"effect":"Convulsion","drugRate":"reported","severity":"unknown"},{"effect":"Parosmia","drugRate":"reported","severity":"unknown"},{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Palpitation","drugRate":"reported","severity":"unknown"},{"effect":"Dry mouth","drugRate":"reported","severity":"unknown"},{"effect":"Malaise","drugRate":"reported","severity":"unknown"},{"effect":"Feeling cold","drugRate":"reported","severity":"unknown"},{"effect":"Cardiac arrest","drugRate":"reported","severity":"unknown"},{"effect":"Nephrogenic Systemic Fibrosis (NSF)","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity reactions","drugRate":"reported","severity":"unknown"},{"effect":"Fatigue","drugRate":"reported","severity":"unknown"},{"effect":"Asthenia","drugRate":"reported","severity":"unknown"},{"effect":"Pain syndromes","drugRate":"reported","severity":"unknown"},{"effect":"Gadolinium associated plaques","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Use only if imaging is essential during pregnancy and cannot be delayed. GBCAs cross the placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive. In animal reproduction studies, although teratogenicity was not observed, embryolethality was observed in monkeys, rabbits and rats receiving intravenous gadobutrol during organogenesis at doses times and above the recommended human dose. Retardation of embryonal development was observed in rabbits and rats receiving intravenous gadobutrol during organogenesis at doses and 12 times, respectively, the recommended human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and is 15% to 20%, respectively.","Geriatric use":"In clinical studies of gadobutrol injection, 1,377 patients were 65 years of age and over, while 104 patients were 80 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, use of gadobutrol injection in elderly patients should be cautious, reflecting the greater frequency of decreased renal function and concomitant medical conditions.","Paediatric use":"The safety and effectiveness of gadobutrol injection have been established in pediatric patients, including term neonates, for use with MRI to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system and for use in MRA to evaluate known or suspected supra-aortic or renal artery disease. Use of gadobutrol injection in these indications is supported by adequate and well-controlled studies in adults and supportive imaging data in pediatric patients."}},"trials":[],"aliases":[],"company":"Bayer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GADOBUTROL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:03:43.313371+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:03:53.999038+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GADOBUTROL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:03:54.825664+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:03:41.242690+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:03:41.242737+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadobutrol injection is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired el","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:03:41.242750+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2218860/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:03:55.439551+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA215061","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:03:41.242754+00:00"}},"allNames":"gadavist","offLabel":[],"synonyms":["gadobutrol","gadavist","gadograf","gadovist","protovist"],"timeline":[{"date":"2011-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BAYER HLTHCARE to Bayer Hlthcare"},{"date":"2011-03-14","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bayer Hlthcare)"},{"date":"2025-04-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Gadavist (Gadobutrol) is a gadolinium-based contrast agent developed by Bayer Healthcare, used for magnetic resonance imaging (MRI). It is a small molecule modality that was FDA approved in 2011 for various MRI indications. Gadavist is off-patent and has generic manufacturers. Key safety considerations include the potential for nephrogenic systemic fibrosis in patients with severe kidney impairment. As a gadolinium-based contrast agent, Gadavist works by enhancing the visibility of internal body structures during MRI.","approvals":[{"date":"2011-03-14","orphan":false,"company":"BAYER HLTHCARE","regulator":"FDA"}],"brandName":"Gadavist","ecosystem":[{"indication":"Magnetic resonance imaging","otherDrugs":[{"name":"ferumoxsil","slug":"ferumoxsil","company":"Amag Pharms Inc"},{"name":"gadodiamide","slug":"gadodiamide","company":"Ge Healthcare"},{"name":"gadoterate meglumine","slug":"gadoterate-meglumine","company":"Guerbet"},{"name":"gadoversetamide","slug":"gadoversetamide","company":"Liebel-Flarsheim"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Magnetic Resonance Contrast Activity","modality":"Small Molecule","drugClass":"Gadolinium-based Contrast Agent [EPC]","explanation":"In MRI, visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with:oDifferences in proton densityoDifferences of the spin-lattice or longitudinal relaxation times (T1)oDifferences in the spin-spin or transverse relaxation time (T2)When placed in magnetic field, Gadavist shortens the T1 and T2 relaxation times. The extent of decrease of T1 and T2 relaxation times, and therefore the amount of signal enhancement obtained from Gadavist, is based upon several factors including the concentration of Gadavist in the tissue, the field strength of the MRI system, and the relative ratio of the longitudinal and transverse relaxation times. At the recommended dose, the T1 shortening effect is observed with greatest sensitivity in T1-weighted magnetic resonance sequences. In T2-weighted sequences the induction of local magnetic field inhomogeneities by the large magnetic moment of gadolinium and at h","oneSentence":"Gadavist works by binding to gadolinium ions, which then accumulate in body tissues and enhance MRI signal.","technicalDetail":"Gadavist is a chelated gadolinium complex that dissociates in the bloodstream, releasing free gadolinium ions that are then taken up by tissues, enhancing T1-weighted MRI signal."},"commercial":{"launchDate":"2011","_launchSource":"DrugCentral (FDA 2011-03-14, BAYER HLTHCARE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4179","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GADOBUTROL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GADOBUTROL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:38:32.565790","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:04:01.190448+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gadopentetate dimeglumine","drugSlug":"gadopentetate-dimeglumine","fdaApproval":"1988-06-02","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadodiamide","drugSlug":"gadodiamide","fdaApproval":"1993-01-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadoteridol","drugSlug":"gadoteridol","fdaApproval":"1992-11-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mangafodipir","drugSlug":"mangafodipir","fdaApproval":"1997-11-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadoversetamide","drugSlug":"gadoversetamide","fdaApproval":"1999-12-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadofosveset","drugSlug":"gadofosveset","fdaApproval":"2008-12-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadopiclenol","drugSlug":"gadopiclenol","fdaApproval":"2022-09-21","patentExpiry":"Sep 19, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"gadobutrol","indications":{"approved":[{"name":"Magnetic resonance imaging","source":"DrugCentral","snomedId":113091000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bayer Hlthcare","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"gadopentetate-dimeglumine","brandName":"gadopentetate dimeglumine","genericName":"gadopentetate dimeglumine","approvalYear":"1988","relationship":"same-class"},{"drugId":"gadodiamide","brandName":"gadodiamide","genericName":"gadodiamide","approvalYear":"1993","relationship":"same-class"},{"drugId":"gadoteridol","brandName":"gadoteridol","genericName":"gadoteridol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mangafodipir","brandName":"mangafodipir","genericName":"mangafodipir","approvalYear":"1997","relationship":"same-class"},{"drugId":"gadoversetamide","brandName":"gadoversetamide","genericName":"gadoversetamide","approvalYear":"1999","relationship":"same-class"},{"drugId":"gadofosveset","brandName":"gadofosveset","genericName":"gadofosveset","approvalYear":"2008","relationship":"same-class"},{"drugId":"gadopiclenol","brandName":"gadopiclenol","genericName":"gadopiclenol","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06854458","phase":"NA","title":"The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-06-27","conditions":["Ischemic Heart Disease (IHD)","Cardiac Magnetic Resonance Imaging","Myocardial Blood Flow"],"enrollment":1000,"completionDate":"2029-03"},{"nctId":"NCT03730051","phase":"PHASE4","title":"Dotarem vs Gadobutrol Contrast for Breast MRI","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-03-01","conditions":["Breast Diseases"],"enrollment":300,"completionDate":"2025-12-31"},{"nctId":"NCT07472491","phase":"PHASE2,PHASE3","title":"A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients","status":"NOT_YET_RECRUITING","sponsor":"GE Healthcare","startDate":"2026-03-31","conditions":["Known or Highly Suspected Central Nervous System (CNS) Lesion","Known or Highly Suspected Body (Excluding CNS) Lesion"],"enrollment":640,"completionDate":"2027-11-30"},{"nctId":"NCT03067467","phase":"","title":"Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-06-01","conditions":["Brain Tumor Adult"],"enrollment":25,"completionDate":"2026-12-31"},{"nctId":"NCT04893434","phase":"PHASE1","title":"Novel Imaging Technique to Assess Gynecologic Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-13","conditions":["Gynecologic Cancer"],"enrollment":20,"completionDate":"2027-05"},{"nctId":"NCT07415018","phase":"NA","title":"Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-07-22","conditions":["Leptomeningeal Disease"],"enrollment":40,"completionDate":"2029-07-31"},{"nctId":"NCT07275814","phase":"PHASE3","title":"A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-11-17","conditions":["For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions"],"enrollment":250,"completionDate":"2026-05"},{"nctId":"NCT04373564","phase":"PHASE4","title":"Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years","status":"RECRUITING","sponsor":"Guerbet","startDate":"2021-03-24","conditions":["Motor Function","Cognitive Function","Contrast Media"],"enrollment":2076,"completionDate":"2028-12-31"},{"nctId":"NCT07275723","phase":"PHASE3","title":"A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-11-14","conditions":["For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)"],"enrollment":306,"completionDate":"2026-05"},{"nctId":"NCT04444128","phase":"","title":"IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION","status":"RECRUITING","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2016-11-15","conditions":["Myocarditis","Heart Failure","Myocardial Fibrosis","Vascular Inflammation","Long COVID Syndrome"],"enrollment":6000,"completionDate":"2030-06-30"},{"nctId":"NCT05229744","phase":"","title":"Prevalence of Endolymphatic Hydrops With a Hitory of Congenital Cytomegalovirus Infection","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-12-15","conditions":["Endolymphatic Hydrops"],"enrollment":18,"completionDate":"2025-04-22"},{"nctId":"NCT05915728","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":["Contrast Enhancement in Magnetic Resonance Imaging","Non-central Nervous System Pathology"],"enrollment":404,"completionDate":"2024-06-01"},{"nctId":"NCT02156739","phase":"NA","title":"Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-13","conditions":["Hepatocellular Carcinoma","Liver and Intrahepatic Bile Duct Disorder","Metastatic Malignant Neoplasm in the Liver","Primary Malignant Liver Neoplasm"],"enrollment":100,"completionDate":"2026-06-01"},{"nctId":"NCT04369560","phase":"EARLY_PHASE1","title":"Virtual Histology of the Bladder Wall for Bladder Cancer Staging","status":"RECRUITING","sponsor":"Jodi Maranchie","startDate":"2025-05-23","conditions":["Urinary Bladder Neoplasms"],"enrollment":42,"completionDate":"2028-12-30"},{"nctId":"NCT07040865","phase":"PHASE4","title":"Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-08-18","conditions":["Suspect Renal and Adrenal Imaging Findings"],"enrollment":104,"completionDate":"2027-07-31"},{"nctId":"NCT04219904","phase":"EARLY_PHASE1","title":"PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-09-07","conditions":["Stage IA Cervical Cancer","Stage IA1 Cervical Cancer","Stage IA2 Cervical Cancer","Stage IB Cervical Cancer","Stage IB1 Cervical Cancer","Stage IB2 Cervical Cancer","Stage IB3 Cervical Cancer"],"enrollment":25,"completionDate":"2027-09-30"},{"nctId":"NCT03986138","phase":"PHASE3","title":"Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Guerbet","startDate":"2019-08-27","conditions":["Lesion in Body Region"],"enrollment":324,"completionDate":"2020-12-09"},{"nctId":"NCT04910425","phase":"PHASE2","title":"PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-06-17","conditions":["Prostate Carcinoma"],"enrollment":0,"completionDate":"2028-07"},{"nctId":"NCT05762367","phase":"NA","title":"MR Lymphatic Imaging in Idiopathic Intracranial Hypertention","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2023-03-10","conditions":["Idiopathic Intracranial Hypertension"],"enrollment":40,"completionDate":"2025-05-11"},{"nctId":"NCT05783271","phase":"NA","title":"Validity of Parametric MRI Using VIRADS","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-12-01","conditions":["Bladder Cancer"],"enrollment":58,"completionDate":"2026-12-31"},{"nctId":"NCT06265272","phase":"","title":"Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-10","conditions":["Liver Cirrhosis","Hepatic Cell Carcinoma","Portal Hypertension"],"enrollment":45,"completionDate":"2026-12-19"},{"nctId":"NCT03996447","phase":"PHASE3","title":"Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Guerbet","startDate":"2019-06-03","conditions":["CNS Lesion","Blood Brain Barrier Defect"],"enrollment":260,"completionDate":"2020-09-11"},{"nctId":"NCT06224543","phase":"PHASE1","title":"MR Image Synthesis With Low Gadobutrol Dose and AI","status":"COMPLETED","sponsor":"Subtle Medical","startDate":"2023-06-16","conditions":["Enhancing Brain Lesions"],"enrollment":60,"completionDate":"2025-08-15"},{"nctId":"NCT05915702","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":["Contrast Enhancement in Magnetic Resonance Imaging","Central Nervous System Pathology"],"enrollment":303,"completionDate":"2024-05-31"},{"nctId":"NCT03504956","phase":"NA","title":"Coronary Atherosclerosis T1-Weighted Characterization (CATCH)","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-07-30","conditions":["Coronary Atherosclerosis"],"enrollment":150,"completionDate":"2026-12-31"},{"nctId":"NCT05811377","phase":"EARLY_PHASE1","title":"Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay","status":"COMPLETED","sponsor":"Christopher J Chermansky, MD","startDate":"2023-03-29","conditions":["IC - Interstitial Cystitis"],"enrollment":8,"completionDate":"2025-05-20"},{"nctId":"NCT06846853","phase":"PHASE4","title":"Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)","status":"RECRUITING","sponsor":"UConn Health","startDate":"2025-03-01","conditions":["Contrast Enhanced Images vs. Non-contrast Images","Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images"],"enrollment":10,"completionDate":"2025-12-25"},{"nctId":"NCT04053842","phase":"PHASE2","title":"Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glenn Bauman","startDate":"2021-02-04","conditions":["Prostate Cancer","Prostate Adenocarcinoma","Prostate Neoplasm"],"enrollment":45,"completionDate":"2025-09"},{"nctId":"NCT06797661","phase":"NA","title":"Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions.","status":"RECRUITING","sponsor":"Erasme University Hospital","startDate":"2025-02-17","conditions":["Glioblastoma","Glioma","Astrocytoma"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT05989022","phase":"NA","title":"Comparison of Low-dose Spiral Breast CT With MRI in Major Indications of MRI for Breast Diagnostics","status":"RECRUITING","sponsor":"AB-CT - Advanced Breast-CT GmbH","startDate":"2023-11-24","conditions":["Breast Cancer Diagnosis"],"enrollment":428,"completionDate":"2025-12"},{"nctId":"NCT06735521","phase":"","title":"Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2024-04-15","conditions":["Univentricular Heart","Microvascular Dysfunction","Heart Failure","Magnetic Resonance"],"enrollment":30,"completionDate":"2025-09-01"},{"nctId":"NCT05215132","phase":"PHASE4","title":"Investigational MRI Clinical Software and Hardware","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2019-12-19","conditions":["Image, Body"],"enrollment":2000,"completionDate":"2026-01-31"},{"nctId":"NCT06731829","phase":"PHASE2","title":"A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-12","conditions":["For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions"],"enrollment":78,"completionDate":"2025-04"},{"nctId":"NCT05515874","phase":"PHASE4","title":"Predicting Stroke Risk in ICAD With Novel MRI","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2021-08-16","conditions":["Intracranial Atherosclerosis"],"enrollment":100,"completionDate":"2026-03-30"},{"nctId":"NCT05685160","phase":"NA","title":"US and MRI of the Forefoot: Intermetatarsal Bursitis or Morton's Neuroma","status":"ENROLLING_BY_INVITATION","sponsor":"Rigshospitalet, Denmark","startDate":"2021-06-14","conditions":["Intermetatarsal Bursitis","Morton Neuroma","Intermetatarsal Neuroma"],"enrollment":75,"completionDate":"2027-03"},{"nctId":"NCT03937921","phase":"","title":"Dotarem Evaluation for Myocardial Perfusion CMR","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2019-07-03","conditions":["Myocardial Perfusion Imaging","Magnetic Resonance Imaging"],"enrollment":90,"completionDate":"2024-10-31"},{"nctId":"NCT05250687","phase":"NA","title":"MR Guided Focused Ultrasound vs Radiotherapy for Palliative Pain Tx in Bone Metastases","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2024-06","conditions":["Bone Metastases"],"enrollment":0,"completionDate":"2024-12"},{"nctId":"NCT05350189","phase":"","title":"A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-11-03","conditions":["Contrast Enhancement in Magnetic Resonance Imaging"],"enrollment":1602,"completionDate":"2023-04-27"},{"nctId":"NCT02358811","phase":"","title":"Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-06-30","conditions":["Obstructive Sleep Apnea (SAOS)","Aging"],"enrollment":69,"completionDate":"2023-04-14"},{"nctId":"NCT03389698","phase":"","title":"Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2018-12-18","conditions":["Alzheimer Disease"],"enrollment":27,"completionDate":"2023-07-11"},{"nctId":"NCT00804128","phase":"","title":"Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-10-01","conditions":["Breast Cancer"],"enrollment":76,"completionDate":"2024-01-05"},{"nctId":"NCT00375830","phase":"PHASE2","title":"Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-01","conditions":["Cancer"],"enrollment":114,"completionDate":"2019-03-14"},{"nctId":"NCT04307186","phase":"PHASE2","title":"Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-11-18","conditions":["Central Nervous System Pathology"],"enrollment":57,"completionDate":"2022-09-06"},{"nctId":"NCT02540967","phase":"","title":"Drug Use Investigation of Gadovist.","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-10-27","conditions":["Magnetic Resonance Imaging","Image Enhancement"],"enrollment":3357,"completionDate":"2017-11-02"},{"nctId":"NCT04575636","phase":"NA","title":"MRL in the Upper Extremity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2020-09-10","conditions":["Lymphedema of Upper Limb"],"enrollment":20,"completionDate":"2023-08-31"},{"nctId":"NCT02095353","phase":"","title":"Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2014-09-01","conditions":["Central Nervous System Neoplasms"],"enrollment":6,"completionDate":"2017-03-07"},{"nctId":"NCT04350957","phase":"NA","title":"Low-dose Imaging Technique (LITE)","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2020-08-24","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2020-08-24"},{"nctId":"NCT03064295","phase":"","title":"Whole-Heart Myocardial Blood Flow Quantification Using MRI","status":"UNKNOWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-03-01","conditions":["Coronary Artery Disease","Coronary Microvascular Disease"],"enrollment":160,"completionDate":"2025-01-01"},{"nctId":"NCT04132843","phase":"NA","title":"Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-01-10","conditions":["Brain Neoplasm","Lymphoma","Metastatic Malignant Neoplasm in the Brain","Recurrent Malignant Brain Neoplasm"],"enrollment":6,"completionDate":"2022-09-01"},{"nctId":"NCT04096261","phase":"","title":"The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease","status":"WITHDRAWN","sponsor":"Charite University, Berlin, Germany","startDate":"2019-09-12","conditions":["Blood Brain Barrier Defect","Sleep Deprivation","Sleep Apnea","Alzheimer Disease"],"enrollment":0,"completionDate":"2019-12-31"},{"nctId":"NCT03731819","phase":"NA","title":"Establishment of Abbreviated Pancreatobiliary MRI Protocol","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-11-05","conditions":["Pancreas Cyst","Intraductal Papillary Mucinous Neoplasm"],"enrollment":30,"completionDate":"2022-05-04"},{"nctId":"NCT05293990","phase":"NA","title":"Usefulness of Gadovist-enhanced FLAIR Imaging","status":"COMPLETED","sponsor":"Ryoo, In Seon","startDate":"2017-02-02","conditions":["Malignant Tumors","Brain Lymphoma","CNS Lymphoma"],"enrollment":60,"completionDate":"2021-01-25"},{"nctId":"NCT02917213","phase":"","title":"Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2016-09","conditions":["Myocardial Infarction","Acute Disease","Thrombosis","Heart Diseases","Stroke"],"enrollment":92,"completionDate":"2022-01-01"},{"nctId":"NCT04093882","phase":"","title":"The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2019-09-12","conditions":["Blood Brain Barrier","Alzheimer Disease","Cognitive Dysfunction","Dementia"],"enrollment":101,"completionDate":"2021-09-30"},{"nctId":"NCT04949321","phase":"NA","title":"Acceleration of the Kinetics of Diffusion of Gadolinium in the Perilymphatic Structures of the Inner Ear.","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2021-07-31","conditions":["Inner Ear ; Meniere's Disease; Imaging"],"enrollment":80,"completionDate":"2023-05-31"},{"nctId":"NCT03602339","phase":"PHASE4","title":"Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-11-14","conditions":["Magnetic Resonance Imaging"],"enrollment":157,"completionDate":"2020-05-26"},{"nctId":"NCT00027170","phase":"","title":"Technical Development of Cardiovascular Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2001-11-26","conditions":["Cardiomyopathy","Congenital Heart Disease","Cardiovascular Disease","Cardiac Magnetic Resonance Imaging","Acute Myocardial Infarction"],"enrollment":8781,"completionDate":"2020-11-19"},{"nctId":"NCT03404648","phase":"PHASE3","title":"Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-11-01","conditions":["Prostate Adenocarcinoma"],"enrollment":19,"completionDate":"2020-01-23"},{"nctId":"NCT01544166","phase":"PHASE1","title":"Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-05-16","conditions":["Magnetic Resonance Imaging"],"enrollment":44,"completionDate":"2013-11-28"},{"nctId":"NCT01655290","phase":"PHASE2","title":"Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2012-08","conditions":["Subacute/Chronic Myocardial Infarction"],"enrollment":20,"completionDate":"2014-06"},{"nctId":"NCT04315584","phase":"EARLY_PHASE1","title":"FDG and FDOPA PET Demonstration of Functional Brain Abnormalities","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2020-03-15","conditions":["Glioblastoma"],"enrollment":5,"completionDate":"2024-06-20"},{"nctId":"NCT01890434","phase":"PHASE3","title":"Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-08-26","conditions":["Coronary Artery Disease"],"enrollment":478,"completionDate":"2016-11-10"},{"nctId":"NCT03910114","phase":"","title":"Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"1990-07-01","conditions":["Magnetic Resonance Imaging Contrast Agents"],"enrollment":500,"completionDate":"2019-04-01"},{"nctId":"NCT03677466","phase":"NA","title":"Intramyocardial Haemorrhage in Patients With Primary STEMI","status":"COMPLETED","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2018-01-25","conditions":["Myocardial Infarction","STEMI","Myocardial Necrosis","Myocardial Injury"],"enrollment":60,"completionDate":"2019-03-20"},{"nctId":"NCT03892681","phase":"NA","title":"Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-04","conditions":["Chronic Hepatitis","Liver Cirrhosis"],"enrollment":129,"completionDate":"2022-12"},{"nctId":"NCT02135861","phase":"PHASE1","title":"A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-30","conditions":["Heart Failure, Congestive"],"enrollment":41,"completionDate":"2017-02-22"},{"nctId":"NCT02796729","phase":"PHASE2","title":"CEST- Glucose Enhanced MRI for Metastatic Brain Tumours","status":"TERMINATED","sponsor":"British Columbia Cancer Agency","startDate":"2016-10","conditions":["Brain Neoplasms, Malignant","Metastasis"],"enrollment":3,"completionDate":"2018-12"},{"nctId":"NCT03057561","phase":"NA","title":"Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance","status":"UNKNOWN","sponsor":"Dipan Shah","startDate":"2016-10-01","conditions":["Coronary Artery Disease","Cardiomyopathy"],"enrollment":120,"completionDate":"2021-06-30"},{"nctId":"NCT01344447","phase":"PHASE3","title":"Gadobutrol Enhanced MRA of the Supra-aortic Vessels","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-05-12","conditions":["Carotid Stenosis"],"enrollment":479,"completionDate":"2014-05-28"},{"nctId":"NCT02902588","phase":"NA","title":"Blood-brain Barrier Permeability Study in Adults With Meningitis","status":"TERMINATED","sponsor":"Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences","startDate":"2015-08-01","conditions":["Blood-Brain Barrier Permeability"],"enrollment":20,"completionDate":"2018-01-31"},{"nctId":"NCT01989000","phase":"NA","title":"The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-11","conditions":["Pancreatic Cancer"],"enrollment":47,"completionDate":"2017-12"},{"nctId":"NCT01890421","phase":"PHASE3","title":"Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07-19","conditions":["Coronary Artery Disease"],"enrollment":426,"completionDate":"2017-08-31"},{"nctId":"NCT02350426","phase":"PHASE1","title":"A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-08-12","conditions":["Arthritis, Rheumatoid"],"enrollment":10,"completionDate":"2016-10-26"},{"nctId":"NCT00522951","phase":"PHASE3","title":"SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":["Brain Metastases"],"enrollment":165,"completionDate":"2008-08"},{"nctId":"NCT02217280","phase":"NA","title":"Dispersal Pattern for Spine Injections (Gadolinium Contrast)","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2015-04","conditions":["Cervical Radiculopathy"],"enrollment":20,"completionDate":"2016-03"},{"nctId":"NCT02967380","phase":"NA","title":"Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2011-12-14","conditions":["Adult Anaplastic (Malignant) Meningioma","Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Choroid Plexus Neoplasm","Adult Diffuse Astrocytoma","Adult Ependymoblastoma","Adult Ependymoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Grade II Meningioma","Adult Medulloblastoma","Adult Mixed Glioma","Adult Oligodendroglioma","Adult Papillary Meningioma","Adult Pineal Gland Astrocytoma","Adult Pineoblastoma","Adult Primary Melanocytic Lesion of Meninges","Adult Supratentorial Primitive Neuroectodermal Tumor","Malignant Adult Intracranial Hemangiopericytoma","Metastatic Malignant Neoplasm in the Brain","Multiple Sclerosis","Recurrent Adult Brain Neoplasm"],"enrollment":14,"completionDate":"2015-10-14"},{"nctId":"NCT01995240","phase":"NA","title":"Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04","conditions":["Pancreatic Cancer"],"enrollment":23,"completionDate":"2017-02"},{"nctId":"NCT02034708","phase":"PHASE4","title":"Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors","status":"COMPLETED","sponsor":"Guerbet","startDate":"2014-06","conditions":["Primary Brain Tumor"],"enrollment":279,"completionDate":"2015-09"},{"nctId":"NCT02294838","phase":"NA","title":"Feasibility Study of MRI Imaging on Parotid Gland Stimulation","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2014-12","conditions":["Parotid Neoplasms"],"enrollment":10,"completionDate":"2017-02"},{"nctId":"NCT01575574","phase":"PHASE4","title":"Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis","status":"COMPLETED","sponsor":"Sara Varea","startDate":"2012-07","conditions":["Hepatocellular Carcinoma"],"enrollment":74,"completionDate":"2016-07"},{"nctId":"NCT00828737","phase":"PHASE4","title":"Safety of Gadovist in Renally Impaired Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":["Fibrosis","Renal Impairment"],"enrollment":927,"completionDate":"2015-01"},{"nctId":"NCT02655718","phase":"NA","title":"Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis","status":"UNKNOWN","sponsor":"Russian Academy of Medical Sciences","startDate":"2015-10","conditions":["Acute Coronary Syndrome"],"enrollment":200,"completionDate":"2018-09"},{"nctId":"NCT02550951","phase":"NA","title":"Utility of MR Lymphangiography in Postoperative Follow-up of Lymphedema: Comparison With Lymphoscintigraphy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2014-10","conditions":["Lymphedema"],"enrollment":7,"completionDate":"2016-10"},{"nctId":"NCT01344460","phase":"PHASE3","title":"Gadobutrol Enhanced MRA of the Renal Arteries","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-05","conditions":["Renal Artery Obstruction"],"enrollment":317,"completionDate":"2012-07"},{"nctId":"NCT02274246","phase":"PHASE1","title":"Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2014-11","conditions":["Left Atrial Fibrosis"],"enrollment":9,"completionDate":"2015-03"},{"nctId":"NCT00468819","phase":"PHASE1","title":"A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":["Magnetic Resonance Imaging"],"enrollment":140,"completionDate":"2008-04"},{"nctId":"NCT01613417","phase":"PHASE4","title":"Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2012-08","conditions":["Brain Disease"],"enrollment":229,"completionDate":"2014-04"},{"nctId":"NCT00395460","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-09","conditions":["Central Nervous System Diseases"],"enrollment":147,"completionDate":"2007-04"},{"nctId":"NCT01095081","phase":"","title":"GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07","conditions":["Magnetic Resonance Imaging","Magnetic Resonance Angiography"],"enrollment":23775,"completionDate":"2013-04"},{"nctId":"NCT01050829","phase":"PHASE3","title":"Gadobutrol Magnevist-controlled Body Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":["Magnetic Resonance Imaging"],"enrollment":370,"completionDate":"2011-04"},{"nctId":"NCT00709852","phase":"PHASE3","title":"Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06","conditions":["Diagnostic Imaging","Central Nervous System Diseases"],"enrollment":402,"completionDate":"2009-04"},{"nctId":"NCT01836055","phase":"","title":"Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist","status":"TERMINATED","sponsor":"Wayne State University","startDate":"2012-01","conditions":["Multiple Sclerosis"],"enrollment":19,"completionDate":"2014-02"},{"nctId":"NCT00764387","phase":"PHASE4","title":"Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-03","conditions":["Neoplastic CNS Lesions"],"enrollment":166,"completionDate":"2009-05"},{"nctId":"NCT01104584","phase":"PHASE3","title":"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":["Breast Cancer"],"enrollment":460,"completionDate":"2012-01"},{"nctId":"NCT01067976","phase":"PHASE3","title":"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-02","conditions":["Breast Cancer","Diagnostic Imaging"],"enrollment":446,"completionDate":"2012-01"},{"nctId":"NCT01660841","phase":"PHASE3","title":"Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":["Magnetic Resonance Imaging"],"enrollment":223,"completionDate":"2013-08"},{"nctId":"NCT01490294","phase":"PHASE2","title":"Myocardial Perfusion MRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":["Myocardial Perfusion Imaging","Magnetic Resonance Imaging"],"enrollment":232,"completionDate":"2006-05"},{"nctId":"NCT00874640","phase":"","title":"Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":["Epidemiologic Factors"],"enrollment":3711,"completionDate":"2011-11"},{"nctId":"NCT00623467","phase":"PHASE3","title":"Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":["Central Nervous System Diseases"],"enrollment":343,"completionDate":"2008-12"},{"nctId":"NCT02036008","phase":"NA","title":"Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2013-08","conditions":["Cancer","Metastases","Liver Neoplasms"],"enrollment":150,"completionDate":"2015-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Gadobutrol"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"gadobutrol"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Gadavist"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000183361","MMSL":"180514","NDDF":"008334","UNII":"1BJ477IO2L","VUID":"4030851","CHEBI":"CHEBI:68841","VANDF":"4030851","INN_ID":"6882","RXNORM":"84990","UMLSCUI":"C0291216","chemblId":"CHEMBL2218860","ChEMBL_ID":"CHEMBL2218860","KEGG_DRUG":"D07420","DRUGBANK_ID":"DB06703","PUBCHEM_CID":"6102852","SNOMEDCT_US":"407976008","MESH_SUPPLEMENTAL_RECORD_UI":"C090600"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"INTRAVENOUS","company":"Bayer HealthCare Pharmaceuticals Inc.","brandName":"Gadavist","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2011-","companyName":"Bayer","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.3 hours","clearance":"2.0 mL/min/kg","fractionUnbound":"1.0%","volumeOfDistribution":"0.22 L/kg"},"publicationCount":711,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"V08CA09","allCodes":["V08CA09"]},"biosimilarFilings":[],"originalDeveloper":"Bayer Hlthcare","recentPublications":[{"date":"2026 Mar 23","pmid":"41866988","title":"Efficacy of a Novel Dimeric Macrocyclic Gadolinium Chelate With High Relaxivity in Preclinical Models of Neurological and Oncological Pathologies.","journal":"Investigative radiology"},{"date":"2026 Mar 19","pmid":"41864344","title":"Safety and T(1) Reactivity for Vasodilator Stress Ferumoxytol-Enhanced Cardiac Magnetic Resonance Imaging.","journal":"Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance"},{"date":"2026 Feb 21","pmid":"41819032","title":"Safety and utility of subcutaneous gadobutrol-enhanced MR lymphography for preoperative mapping in lymphovenous anastomosis: A phase II trial.","journal":"Journal of plastic, reconstructive & aesthetic surgery : JPRAS"},{"date":"2026 Feb 20","pmid":"41720517","title":"Gadolinium-Enhanced Portable Ultra-Low Field MRI for Evaluating Various Intracranial Pathologies.","journal":"AJNR. American journal of neuroradiology"},{"date":"2026 Feb 15","pmid":"41698691","title":"LC-MS/MS-Based Determination of Gadobutrol Residues for Pharmaceutical Cleaning Validation.","journal":"PDA journal of pharmaceutical science and technology"}],"companionDiagnostics":[],"genericManufacturers":2,"_genericFilersChecked":true,"genericManufacturerList":["Hainan Poly Pharm","Hengrui Pharma"],"status":"approved","companyName":"Bayer Hlthcare","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"2011","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-03-14T00:00:00.000Z","mah":"BAYER HLTHCARE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":12,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:04:01.190448+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}